Sentence,class,file
"Biochemia Medica 2014;24(1):123–37  http://dx.doi.org/10.11613/BM.2014.014  132Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions ated with high risk for developing SBP .",Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"http://dx.doi.org/10.11613/BM.2014.014 Biochemia Medica 2014;24(1):123–37    133Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions cificity in identifying exudates of 98% and 72%,  respectively.",OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"Biochemia Medica 2014;24(1):123–37  http://dx.doi.org/10.11613/BM.2014.014  134Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions the document C49-A: Analysis of body fluids in  clinical chemistry.",Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Med Clin N Am 2011;95:1055-70. http://dx.doi.org/10.1016/j.mcna.2011.08.005.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
http://www.acbi.ie/.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
N Engl J Med 2002;346:1971-7. http://dx.doi.org/10.1056/NEJMcp010731.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Clin Chim Acta 2004;343:61-84. http://dx.doi.org/10.1016/j.cccn.2004.02.002.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Crit Care 2011;20:119-28. http://dx.doi.org/10.4037/ajcc2011685.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
http://dx.doi.org/10.1016/S1526- 0542(04)90039-5.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1990;98:546-9. http://dx.doi.org/10.1378/chest.98.3.546.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"http://dx.doi.org/10.11613/BM.2014.014 Biochemia Medica 2014;24(1):123–37    135Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions 10.",Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Ann Clin Biochem 2001;38:311-22. http://dx.doi.org/10.1258/0004563011900812.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1987;92:296-302. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1993;104:399-404.  http://dx.doi.org/10.1378/chest.104.2.399.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1995;107:1604-9.http://dx.doi.org/10.1378/chest.107.6.1604.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Ann Clin Biochem 2001;38:671-5. http://dx.doi.org/10.1258/0004563011901082.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1995;108:1260-3. http://dx.doi.org/10.1378/ chest.108.5.1260.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Respiratory Medicine 2011;105:1712-7. http://dx.doi.org/10.1016/j.rmed.2011.07.015.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Clin Chim Acta 1997;264:149-62. http://dx.doi.org/10.1016/S0009-8981(97)00091-0.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Med 2004;116:417-20. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Med 2001;110:681-6. http://dx.doi.org/10.1016/S0002-9343(01)00726-4.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Resp Med 2010;104:1092-100. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2009;136:671-7. http://dx.doi.org/10.1378/chest.09- 0270.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Eur Respir J 2006;28:144-50. http://dx.doi.org/10.1183/09031936.06.00113205.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Inter Med 2008;47:1669-74. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1997;111:970-80. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2002;121:1916-20. http://dx.doi.org/10.1378/chest.121.6.1916.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Respir Crit Care Med 2003;167:1591-9. http://dx.doi.org/10.1164/rccm.200301-048PP .,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Resp Med 2006;100:1960-5. http://dx.doi.org/10.1016/j.rmed.2006.02.025.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Res - pirology 2012;17:270-7. http://dx.doi.org/10.1111/j.1440- 1843.2011.02100.x.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
http://dx.doi.org/10.1136/thx.58.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Curr Opin Pulm Med 2010;16:387-93. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Curr Opin Pulm Med 2010;16:367-75. http://dx.doi.org/10.1097/MCP .0b013e32833a7154.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2007;131:1133- 41.http://dx.doi.org/10.1378/chest.06-2273.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Eur Respir J 2008;31:1098-106. http://dx.doi.org/10.1183/09031936.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
He - art Lung 2010;39:540-3. http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"Biochemia Medica 2014;24(1):123–37  http://dx.doi.org/10.11613/BM.2014.014  136Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions 38.",Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Respir Med 2008;102:744-54. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Cancer  1999;86:1488-95. http://dx.doi.org/10.1002/(SICI)1097- 0142(19991015)86:8<1488::AID-CNCR15>3.0.CO;2- Y.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2004;126:1757-63. http://dx.doi.org/10.1378/ chest.126.6.1757.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2002;121:470-4. http://dx.doi.org/10.1378/chest.121.2.470.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Arch Intern Med 2001;161:228-32. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Clin Chest Med 2006;27:309-19. http://dx.doi.org/10.1016/j.ccm.2005.12.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Respir Med 2007;101:910-18. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Ann Clin Bio - chem 2010;47:397-407. http://dx.doi.org/10.1258/acb.2010.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Hepatology 2004;39:841-56. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Clin Med JRCPL 2002;2:310-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Ann Int Med 1992;117:215-20. http://dx.doi.org/10.7326/0003-4819-117-3-215.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Dig Dis Sci 2000;45:500-8. http://dx.doi.org/10.1023/A:1005437005811.52.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Ann Clin Biochem 2007;44:471-3. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
J  Hepatol 2000;32:142-53. http://dx.doi.org/10.1016/S0168- 8278(00)80201-9.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Liver International 2005;25:1197- 201. http://dx.doi.org/10.1111/j.1478-3231.2005.01176.x.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Sao Pau-lo Med J 2006;124:141-4. http://dx.doi.org/10.1590/S1516- 31802006000300006.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Hepatology 2003;37:893-96. http://dx.doi.org/10.1053/jhep.2003.50120.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
J Int Med Res 2009;37:79-86. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Available at: http://www.mdconsult.com/books.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
J Am Coll Surg 2008;207:751-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"http://dx.doi.org/10.11613/BM.2014.014 Biochemia Medica 2014;24(1):123–37    137Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions 66.",Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Gyne - col Oncol 2012;127:191-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
J Clin Gastroenterol 2006;40:705-10. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1997;111:1213-21. http://dx.doi.org/10.1378/chest.111.5.1213.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 2002;121:495-9. http://dx.doi.org/10.1378/ chest.121.2.495.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Med 2005;118:636- 40. http://dx.doi.org/10.1016/j.amjmed.2005.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Am J Cardiol 2007;99:1294-7. http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Acta Tropica 2006;99:67-74. http://dx.doi.org/10.1016/j.actatropica.2006.07.004.,OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Available at: http://www.calgarylabservices.com/edu-cation-research/medical-professionals-education.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
Chest 1998;114:1368-72. http://dx.doi.org/10.1378/ chest.114.5.1368.,Non-OADS,/arxiv_data1/oa_pdf/1f/b7/biochem-24-1-123-15.PMC3936968.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010  80Abstract The use of contrast media such as organic iodine molecules and gadolinium contrast agents is commonplace in diagnostic imaging.",Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
http://dx.doi.org/10.11613/BM.2014.010 Biochemia Medica 2014;24(1):80–8    81Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010  82Lippi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
http://dx.doi.org/10.11613/BM.2014.010 Biochemia Medica 2014;24(1):80–8    83Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010  84Lippi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
http://dx.doi.org/10.11613/BM.2014.010 Biochemia Medica 2014;24(1):80–8    85Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010  86Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
http://dx.doi.org/10.11613/BM.2014.010 Biochemia Medica 2014;24(1):80–8    87Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochem Med  2010;20:126-30. http://dx.doi.org/10.11613/BM.2010.014.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochem Med  2012;22:145-9. http://dx.doi.org/10.11613/BM.2012.017.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochem Med (Zagreb) 2010;20:147-53. http://dx.doi.org/10.11613/ BM.2010.017.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2007;53:1338-42. http://dx.doi.org/10.1373/clinchem.2007.088344.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Available at: http://www.ifcc.org/ifccfi- les/docs/130401002end.pdf .,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Bi-ochem Med 2010;20:154-9. http://dx.doi.org/10.11613/ BM.2010.018.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochem Med 2011;21:160-6.  http://dx.doi.org/10.11613/BM.2011.025.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Ann Clin Bi- ochem 2011;48:418-32. http://dx.doi.org/10.1258/ acb.2011.011073.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem Lab Med 2011;49:2001-6. http://dx.doi.org/10.1515/CCLM.2011.702.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem Lab Med 2010;48:1681-2. http://dx.doi.org/10.1515/ CCLM.2010.312.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Bioanalysis 2013;5:1571-82. http://dx.doi.org/10.4155/ bio.13.110.17.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
J Clin Lab Anal 2011;25:244-5. http://dx.doi.org/10.1002/jc- la.20466.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Eur J Radiol 2008;66:160-7. http://dx.doi.org/10.1016/j.ejrad.2008.01.023.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Curr Med Chem 2012;19:736-43. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2003;49:1187-9. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2012;58:1604-5. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
J Clin Lab Anal 2012;26:246-7. http://dx.doi.org/10.1002/jcla.21512.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Kaohsiung J Med Sci 2006;22:107-13.  http://dx.doi.org/10.1016/S1607-551X(09)70229-3.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2005;51:273-4. http://dx.doi.org/10.1373/clinchem.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2006;52:2312-3. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Lab Me - dicine 2011;42:602-6. http://dx.doi.org/10.1309/LMHZLI- MXVYLWT7S Q.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chim Acta 1999;281:71-6. http://dx.doi.org/10.1016/ S0009-8981(98)00207-1.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010  88Lippi G. et al.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Scand J Clin Lab Invest 1995;55:421-6. http://dx.doi.org/10.3109/00365519509104981 .,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
J Pharm Biomed Anal 1999;21:931-43. http://dx.doi.org/10.1016/S0731-7085(99)00188-0.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Radiology 2003;227:639-46. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Nephrol Dial Transplant 2005;20:1516-7. http://dx.doi.org/10.1093/ndt/gfh902.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Mayo Clin Proc  2005;80:1655-7. http://dx.doi.org/10.4065/80.12.1655.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Clin Chem 2004;50:741-6. http://dx.doi.org/10.1373/ clinchem.2003.028886.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Am J Clin Pathol 2004;121:282-92. http://dx.doi.org/10.1309/MGA3LC4X8CGLX9CH.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
AJR Am J Roentgenol 2007;189:1539-44. http://dx.doi.org/10.2214/ AJR.07.2464.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
In-vest Radiol 2011;46:366-9. http://dx.doi.org/10.1097/ RLI.0b013e318209ed6f .44.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Br J Radiol 2009;82:438-9. http://dx.doi.org/10.1259/bjr/13806057.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Ann Clin Biochem 2011;48:2:176-7. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
"Darby D, Broomhead C. Interference with serum indices  measurement, but not chemical analysis, on the Roche Mo - dular by Patent Blue V. Ann Clin Biochem 2008;45:289-92.  http://dx.doi.org/10.1258/acb.2007.007176.",OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Ann Clin Biochem 2012;49:510-1. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Biochem Med 2010;20:131-43. http://dx.doi.org/10.11613/BM.2010.015.,OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Adv Med Sci 2012;57:341-7. http://dx.doi.org/10.2478/ v10039-012-0045-3.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
J Thromb Thrombolysis  2010;30:459-71. http://dx.doi.org/10.1007/s11239-010- 0460-x.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
Available at: http://www.esur.org/guidelines/en/index.php.,Non-OADS,/arxiv_data1/oa_pdf/2d/36/biochem-24-1-80-11.PMC3936969.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.012 Biochemia Medica 2014;24(1):105–13    105Abstract Quality indicators (QIs) measure the extent to which set targets are attained and provide a quantitative basis for achieving improvement in care  and, in particular, laboratory services.",Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Biochemia Medica 2014;24(1):105–13  http://dx.doi.org/10.11613/BM.2014.012  106Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.11613/BM.2014.012 Biochemia Medica 2014;24(1):105–13    107Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Biochemia Medica 2014;24(1):105–13  http://dx.doi.org/10.11613/BM.2014.012  108Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.11613/BM.2014.012 Biochemia Medica 2014;24(1):105–13    109Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Biochemia Medica 2014;24(1):105–13  http://dx.doi.org/10.11613/BM.2014.012  110Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.11613/BM.2014.012 Biochemia Medica 2014;24(1):105–13    111Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Biochemia Medica 2014;24(1):105–13  http://dx.doi.org/10.11613/BM.2014.012  112Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Int J Qual Health Care 2003;15:523-30. http://dx.doi.org/10.1093/intqhc/mzg081.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2013;51:39-46. http://dx.doi.org/10.1515/cclm-2012-0094.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem 2007;53:1338-42. http://dx.doi.org/10.1373/clinchem.2007.088344.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Bio - chem 2013;46:1170-4. http://dx.doi.org/10.1016/j .,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2012;50:1755-60. http://dx.doi.org/10.1515/cclm-2012- 0150.12.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2013;51:187-95. http://dx.doi.org/10.1515/cclm- 2012-0582.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Available at: http://www.rcpaqap.com.au/kimms/.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Vox Sanguinis 2011;100:298-302.  http://dx.doi.org/10.1111/j.1423-0410.2010.01391.x.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2009;47:143-53. http://dx.doi.org/10.1515/ CCLM.2009.045.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2008;46:764-72. http://dx.doi.org/10.1515/ CCLM.2008.170.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2011; 49:1113-26. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.11613/BM.2014.012 Biochemia Medica 2014;24(1):105–13    113Plebani M. et al.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
"Clin Chem 2012, 58:638-42. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.1016/j.cca.2013.09.051.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2007;45:712-9.  http://dx.doi.org/10.1515/CCLM.2007.173.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
2003;333:169-76. http://dx.doi.org/10.1016/ S0009-8981(03)00181-5.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Qual Saf Health Care 2008;17:194-200. http://dx.doi.org/10.1136/qshc.2006.021915.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Ann In-tern Med 2006;145:488-96. http://dx.doi.org/10.7326/0003- 4819-145-7-200610030-00006.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
BMC Fam Pract 2007;8:22-32. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Ann Clin Biochem 2012;49:323-36. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.1309/AJCPJF8JI4ZL - DQUE .,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.1016/j.cca.2009.03.025.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
http://dx.doi.org/10.1515/ CCLM.2011.128.,Non-OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
Clin Chem Lab Med 2013;51:741-51. http://dx.doi.org/10.1515/cclm-2013-0075.,OADS,/arxiv_data1/oa_pdf/63/63/biochem-24-1-105-13.PMC3936970.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Abstract Logistic regression is used to obtain odds ratio in the presence of more than one explanatory variable.",Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
"Key words : regression analysis; logistic regression; odds ratio; variable selection Received: September 06, 2013 Accepted: November 26, 2013Understanding logistic regression analysis Sandro Sperandei School of Physical Education and Sports – Federal University of Rio de Janeiro, Rio de Janeiro, Brazil Corresponding author: ssperandei@gmail.comLessons in biostatistics Biochemia Medica 2014;24(1):12–8  http://dx.doi.org/10.11613/BM.2014.003  12Introduction One of the previous topics in Lessons in biostatistics  presented the calculation, usage and interpreta - tion of odds ratio statistic and greatly demonstrat - ed the simplicity of odds ratio in clinical practice  (1).",Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.org/10.11613/BM.2014.003 Biochemia Medica 2014;24(1):12–8    13Sperandei S. Logistic regression analysis whether the treatment effect on endocarditis re - sult is being masked by the effect of age?,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
"Biochemia Medica 2014;24(1):12–8  http://dx.doi.org/10.11613/BM.2014.003  14Sperandei S. Logistic regression analysis confounding effects, as was demonstrated in the  example above when the effect of treatment on death probability was partially hidden by the ef - fect of age.",Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.org/10.11613/BM.2014.003 Biochemia Medica 2014;24(1):12–8    15Sperandei S. Logistic regression analysis the same outcome.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
Biochemia Medica 2014;24(1):12–8  http://dx.doi.org/10.11613/BM.2014.003  16Sperandei S. Logistic regression analysis tis decreases by 25%.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
"http://dx.doi.org/10.11613/BM.2014.003 Biochemia Medica 2014;24(1):12–8    17Sperandei S. Logistic regression analysis On the other hand, some variables have no clear  reference level, but present ordered levels and the reference level will be, usually, one of the end - points or, less frequently, the central level.",Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
"Biochemia Medica 2014;24(1):12–8  http://dx.doi.org/10.11613/BM.2014.003  18Sperandei S. Logistic regression analysis So, it is importance to pay attention to the setup of  the reference levels.",Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.org/10.11613/BM.2013.003.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.org/10.1080/01621459.1979.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
http://dx.doi.org/10.1111/j.1464-5491.2012.03590.x.,Non-OADS,/arxiv_data1/oa_pdf/85/f5/biochem-24-1-12-4.PMC3936971.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Abstract Authors of articles published in medical journals are often busy researchers who cannot afford time devoted to writing.",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"Natasha Das*1, Saurendra Das2 1Freelance Medical Writer, Delhi, India 2Excel Life Sciences, NOIDA, India *Corresponding author: drnatashadas@gmail.comResearch integrity corner http://dx.doi.org/10.11613/BM.2014.004 Biochemia Medica 2014;24(1):19–24    19Introduction Medical authors try to communicate the results of  their research, clinical practice or thinking to their colleagues by writing about it in medical journals.",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"Biochemia Medica 2014;24(1):19–24  http://dx.doi.org/10.11613/BM.2014.004  20Das N, Das S. Medical writers and ghostwriters Should the writer be included as an author of •	 the paper?",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"http://dx.doi.org/10.11613/BM.2014.004 Biochemia Medica 2014;24(1):19–24    21Das N, Das S. Medical writers and ghostwriters experts in the niche field as well as by people from  other disciplines.",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"Biochemia Medica 2014;24(1):19–24  http://dx.doi.org/10.11613/BM.2014.004  22Das N, Das S. Medical writers and ghostwriters tigators, the sponsoring company is encouraged  to identify a ‘writing group’ or the named authors who collaborate with the professional writer in de - veloping the manuscript for publication (9).",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"http://dx.doi.org/10.11613/BM.2014.004 Biochemia Medica 2014;24(1):19–24    23Das N, Das S. Medical writers and ghostwriters The World Association of Medical Editors (WAME)  recommends journal editors to modify their In - structions for Authors to mention that medical writers’ contributions can be legitimate and should be mentioned in the acknowledgement section  (16).",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"Biochemia Medica 2014;24(1):19–24  http://dx.doi.org/10.11613/BM.2014.004  24Das N, Das S. Medical writers and ghostwriters References  1.",Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
AJR Am J Roen- tgenol 2002;179:1099-100. http://dx.doi.org/10.2214/ajr.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Clin Experiment Opht- halmol 2009;37:864-7. http://dx.doi.org/10.1111/j.1442- 9071.2009.02190.x.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Chest  2006;129:1098-9. http://dx.doi.org/10.1378/chest.129.4.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Curr Med Res Opin 2005;21:317-22. http://dx.doi.org/10.1185/  030079905X25578.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Curr Med Res Opin 2005;21:307-10. http://dx.doi.org/10.1185/  030079905X28944.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Mens Sana Mo - nogr 2008;6:257-73. http://dx.doi.org/10.4103/0973-1229.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Curr Med Res Opin 2003;19:149-54. http://dx.doi.org/10.1185/030079903125001767.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Am J Health Behav 2005;29:579-87. http://dx.doi.org/10.5993/AJHB.29.6.12.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
The American Journal of Sports Medicine 2010;38:2183-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Avai-lable at: http://www.icmje.org/ethical_1author.html.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Available at: http://www.wame.org/resources/policies#ghost.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Available at: http://www.councilscienceeditors.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
Available at:  http://publicationethics.org/files/u7140/Authorship%20problems_0.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c6/fe/biochem-24-1-19-5.PMC3936972.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.018 Biochemia Medica 2014;24(1):159–66    159Abstract Introduction : Additional nucleotide substitutions in the 3´-untranslated region of prothrombin gene could explain some thrombotic events and  also adverse pregnancy outcomes.",Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Biochemia Medica 2014;24(1):159–66  http://dx.doi.org/10.11613/BM.2014.018  160Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
http://dx.doi.org/10.11613/BM.2014.018 Biochemia Medica 2014;24(1):159–66    161Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Sequences of oligonucleotides used for amplification and se - quencing were deduced from the published Hu - man Genome sequence (http://genome.ucsc.edu).,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Biochemia Medica 2014;24(1):159–66  http://dx.doi.org/10.11613/BM.2014.018  162Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
http://dx.doi.org/10.11613/BM.2014.018 Biochemia Medica 2014;24(1):159–66    163Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Biochemia Medica 2014;24(1):159–66  http://dx.doi.org/10.11613/BM.2014.018  164Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
http://dx.doi.org/10.11613/BM.2014.018 Biochemia Medica 2014;24(1):159–66    165Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Thromb Res 2006;118:767-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Mol Dia- gn 2003;5:250-3. http://dx.doi.org/10.1016/S1525-1578- (10)60482-5.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Haemost 2009;7:1585-7. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Haemost 2006;4:2285-7. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Lab Hematol 2006;12:131-3. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Haemost 2007;5:1064-8.  http://dx.doi.org/10.1111/j.1538-7836.2007.02478.x.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Hae - most 2005;3:806-8. http://dx.doi.org/10.1111/j.1538-7836 .2005.01241.x.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Diagn Mol Pathol 2002;11:152-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Haemost 2006;4:1078-85. http://dx.doi.org/10.1111/j.1538-7836.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Arch In-tern Med 2006;166:729-36. http://dx.doi.org/10.1001/ archinte.166.7.729.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Blood Coagul Fi-brinolysis 2006;17:599-602. http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Biochemia Medica 2014;24(1):159–66  http://dx.doi.org/10.11613/BM.2014.018  166Izquierdo Álvarez S. et al.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Clin Lab Ha-ematol 2005;27:343-6. http://dx.doi.org/10.1111/j.1365- 2257.2005.00720.x.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
J Thromb Haemost 2003;1:2683-5. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Clin Chem 2009;55:739- 47. http://dx.doi.org/10.1373/clinchem.2008.112102.,OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
Pe - diatric Hematol Oncol 2005;22:309-14. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/8d/biochem-24-1-159-19.PMC3936973.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    57Abstract In the clinical laboratory setting, interferences can be a significant source of laboratory errors with potential to cause serious harm for the patient.",Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochemia Medica 2014;24(1):57–67  http://dx.doi.org/10.11613/BM.2014.008  58Nikolac N. Lipemia interference Causes of lipemia Lipemia is a turbidity of the sample caused by ac - cumulation of lipoprotein particles.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    59Nikolac N. Lipemia interference tients in intensive care units (16).,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"Biochemia Medica 2014;24(1):57–67  http://dx.doi.org/10.11613/BM.2014.008  60Nikolac N. Lipemia interference Non-homogeneity of the sample For obtaining serum or plasma for analyte meas - urement, blood needs to be centrifuged.",Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    61Nikolac N. Lipemia interference few shortcomings.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"Biochemia Medica 2014;24(1):57–67  http://dx.doi.org/10.11613/BM.2014.008  62Nikolac N. Lipemia interference tient, an additional visual inspection of the sample  might help in determining the origin of turbidity.",Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    63Nikolac N. Lipemia interference er than 85%: GGT – gamma-glutamyltransferase,  CK-MB – creatine kinase MB isoenzyme and CRP (using Beckman Coulter reagents), and therefore can’t be measured in the sample after treatment with Lipoclear reagent (48).",Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochemia Medica 2014;24(1):57–67  http://dx.doi.org/10.11613/BM.2014.008  64Nikolac N. Lipemia interference lem with Intralipid lies in its particle size.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    65Nikolac N. Lipemia interference their Letter to the editor emphasizing importance  of using evidence based criteria based on biologi - cal variation (59).,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochemia Medica 2014;24(1):57–67  http://dx.doi.org/10.11613/BM.2014.008  66Nikolac N. Lipemia interference References  1.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.1515/cclm-2012-0597.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med 2008;46:764-72. http://dx.doi.org/10.1515/ CCLM.2008.170.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med 2010;48:63-6. http://dx.doi.org/10.1515/ CCLM.2010.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med 2011;49:1113-26. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Semin Thromb Hemost 2012;38:553-8. http://dx.doi.org/10.1055/ s-0032-1315960.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Diabetes 2003;52:453-62. http://dx.doi.org/10.2337/diabetes.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochem Med 2013;23:326-31. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochem Med 2013;23:242-54. http://dx.doi.org/10.11613/ BM.2013.031.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.hkmb.hr/povjerenstva/strucna-pitanja.html#1.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Expert Opin Drug Deliv 2013;10:1533-49.  http://dx.doi.org/10.1517/17425247.2013.824874.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Toxicol (Phila) 2013;51:896-8. http://dx.doi.org/10.3109/15563650.2013.831436.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Toxicol (Phila)  2013;51:501-4. http://dx.doi.org/10.3109/15563650.2013.8 03229.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.drugs.com/pro/intrali-pid.html.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.intecho - pen.com/books/advances-in-immunoassay-technology/interference-in-immunoassays.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"Berlin, Boston: De Gruyter, 2012. http://dx.doi.org/10.1515/  9783110266221.",Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem 2004;50:1968-9. http://dx.doi.org/10.1373/clinchem.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Biochem 2008;41:1486-8. http://dx.doi.org/10.1016/j.clinbiochem.2008.09.111.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: https://ahdc.vet.cornell.edu/clinpath/modules/chem/volume.htm.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67    67Nikolac N. Lipemia interference 30.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Electrolyte & Blood Pressure 2006;4:77-82.  http://dx.doi.org/10.5049/EBP .2006.4.2.77.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Amsterdam: Elsevier 2013; p. 53-62. http://dx.doi.org/10.1016/B978-0-12-415783-5.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Biochem 2012;45:372-3. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med  2009;47:1361-5. http://dx.doi.org/10.1515/CCLM.2009.306.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
J Clin Pathol 2003;56:861-2. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med  2006;44:220-2. http://dx.doi.org/10.1515/CCLM.2006.040.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochem Med 2012;22:352-62. http://dx.doi.org/10.11613/BM.2012.037.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"Darby D, Broomhead C. Interference with serum indices measurement, but not chemical analysis, on the Roche Mo - dular by Patent Blue V. Ann Clin Biochem 2008;45:289-92.  http://dx.doi.org/10.1258/acb.2007.007176.",OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochem Med 2011;21:160-6.  http://dx.doi.org/10.11613/BM.2011.025.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Biochem Med 2011;21:86-92. http://dx.doi.org/10.11613/BM.2011.016.45.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.statspin.com/pdfs/64-003957-001D.pdf.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.statspin.com/pdfs/64-005075- 001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin  Chem Lab Med 2007;45:114-9. http://dx.doi.org/10.1515/ CCLM.2007.004.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
J Clin Pathol 1988;41:1026-7.  http://dx.doi.org/10.1136/jcp.41.9.1026.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Available at: http://www.westgard.com/bioda- tabase1.htm.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chem Lab Med 2006;44:413-9. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Toxicol (Phila) 2012;50:812-7. http://dx.doi.org/10.310 9/15563650.2012.731509.,Non-OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
Clin Chim Acta 2011;412:1550-3. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/53/09/biochem-24-1-57-9.PMC3936974.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.000 Biochemia Medica 2014;24(1):5    5Editorial ©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine.",Non-OADS,/arxiv_data1/oa_pdf/9a/48/biochem-24-1-5-1.PMC3936975.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biochemia Medica indexed in PubMed Central (PMC) Ana-Maria Simundic Editor-in-chief, Biochemia Medica, Zagreb, Croatia As announced in the last journal issue (1), with  great pleasure we wish to inform you that Bio- chemia Medica has just been accepted for indexing in PubMed Central (PMC) journal database (http://www.ncbi.nlm.nih.gov/pmc/).",Non-OADS,/arxiv_data1/oa_pdf/9a/48/biochem-24-1-5-1.PMC3936975.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.020 Biochemia Medica 2014;24(1):175–9    175Abstract Introduction : In this work we report on the possible effect of the medical therapy on CDT concentration in a chronic alcohol abuser, with known  medical history (July 2007 – April 2012) and alcohol abuse confirmed by relatives.",Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Biochemia Medica 2014;24(1):175–9  http://dx.doi.org/10.11613/BM.2014.020  176Vidali M. et al.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
http://dx.doi.org/10.11613/BM.2014.020 Biochemia Medica 2014;24(1):175–9    177Vidali M. et al.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Biochemia Medica 2014;24(1):175–9  http://dx.doi.org/10.11613/BM.2014.020  178Vidali M. et al.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
http://dx.doi.org/10.11613/BM.2014.020 Biochemia Medica 2014;24(1):175–9    179Vidali M. et al.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Alcohol Alcohol 2008;43:436-41. http://dx.doi.org/10.1093/alcalc/agn017.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Clin Chim Acta 2008;389:164-6. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Clin  Chim Acta 2008;388:59-67. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Clin Chem  Lab Med 2008;46:1759-62. http://dx.doi.org/10.1515/ CCLM.2008.346.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Clin Chem Lab Med 2007;45:558-62. http://dx.doi.org/10.1515/ CCLM.2007.107.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Alcohol Clin Exp Res 2004;28:1347-55. http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Pharmacotherapy 2004;24:831-7. http://dx.doi.org/10.1592/phco.24.9.831.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Alcohol Alcohol 2004;39:75-85. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
J Toxi-col Environ Health B Crit Rev 2004;7:319-37. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
J Chromatogr B Anal-yt Technol Biomed Life Sci 2006;841:96-109. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Clin Chem 2007;53:1115-21. http://dx.doi.org/10.1373/ clinchem.2006.084459.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Electrophoresis 2008;29:260-8. http://dx.doi.org/10.1002/elps.200700708.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
Alco - hol Alcohol 2010;46:123-7. http://dx.doi.org/10.1093/al- calc/agq092.,OADS,/arxiv_data1/oa_pdf/99/4d/biochem-24-1-175-21.PMC3936976.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biochemia Medica 2014;24(1):138–45  http://dx.doi.org/10.11613/BM.2014.015  138Abstract Background : The ultra-large von Willebrand factor (vWF) multimers are very active and must be degraded by ADAMTS13 for optimal activity.",Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
http://dx.doi.org/10.11613/BM.2014.015 Biochemia Medica 2014;24(1):138–45    139Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Biochemia Medica 2014;24(1):138–45  http://dx.doi.org/10.11613/BM.2014.015  140Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
http://dx.doi.org/10.11613/BM.2014.015 Biochemia Medica 2014;24(1):138–45    141Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Biochemia Medica 2014;24(1):138–45  http://dx.doi.org/10.11613/BM.2014.015  142Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
http://dx.doi.org/10.11613/BM.2014.015 Biochemia Medica 2014;24(1):138–45    143Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Biochemia Medica 2014;24(1):138–45  http://dx.doi.org/10.11613/BM.2014.015  144Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
http://dx.doi.org/10.11613/BM.2014.015 Biochemia Medica 2014;24(1):138–45    145Kilercik M. et al.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Nephrol Dial Transplant 2004;19:1687-93. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Blood 2002;99:3971-7. http://dx.doi.org/10.1182/blood-2001-11-0060 .,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Pediatr Nephrol 2009;24:19- 29. http://dx.doi.org/10.1007/s00467-008-0863-5.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Br J Haematol 2013;163:514-9. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Semin Thromb Hemost 2009;35:120-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Ann Epidemi- ol 1992;2:723-33. http://dx.doi.org/10.1016/1047-2797- (92)90017-K .,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Clin Chem 2003;49:963-5. http://dx.doi.org/10.1373/49.6.963.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Biochem Med 2009;19:250-9. http://dx.doi.org/10.11613/ BM.2009.023.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
J Thromb Haemost 2006;4:2556-62. http://dx.doi.org/10.1111/j.1538- 7836.2006.02273.x.,OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
Available at: http://www.westgard.com/biodatabase1.htm.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
http://dx.doi.org/10.1373/ clinchem.2012.187781.,Non-OADS,/arxiv_data1/oa_pdf/68/d2/biochem-24-1-138-16.PMC3936977.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.019 Biochemia Medica 2014;24(1):167–74    167Abstract Hemoglobin (Hb) Grey Lynn is a Hb variant caused by a substitution of Phe for Leu at position 91 of α1-globin chain, originally described in individual  of unknown ethnic background.",Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Biochemia Medica 2014;24(1):167–74  http://dx.doi.org/10.11613/BM.2014.019  168Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
"The PCR product was digested to completion with Hind III restriction enzyme (5’-A ▼AGCTT-3’) (New  England Biolabs, Beverly, MA, USA) (NEBcutter V2.0, http://tools.neb.com/NEBcutter2/).",Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.org/10.11613/BM.2014.019 Biochemia Medica 2014;24(1):167–74    169Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Biochemia Medica 2014;24(1):167–74  http://dx.doi.org/10.11613/BM.2014.019  170Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.org/10.11613/BM.2014.019 Biochemia Medica 2014;24(1):167–74    171Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Biochemia Medica 2014;24(1):167–74  http://dx.doi.org/10.11613/BM.2014.019  172Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.org/10.11613/BM.2014.019 Biochemia Medica 2014;24(1):167–74    173Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Orphanet J  Rare Dis 2010;5:13. http://dx.doi.org/10.1186/1750-1172- 5-13.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Available at http://globin.bx.psu.edu/Hbvar/menu.html.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.org/10.1101/cshperspect.a011684.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Int J Lab Hematol 2011;33:424-33. http://dx.doi.org/10.1111/ j.1751-553X.2011.01301.x.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Nat Rev Genet 2001;2:245-55. http://dx.doi.org/10.1038/35066048.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Clin Chem 2007;53:990-1. http://dx.doi.org/10.1373/clinchem.2006.084939.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Blood 2006;107:1747-50. http://dx.doi.org/10.1182/ blood-2005-07-3046.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
"Oxford, UK: Blackwell; 2001. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Hum Genet 1989;84:41-6. http://dx.doi.org/10.1007/BF00210668.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
http://dx.doi.org/10.1159/000076523.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Hemoglo - bin 2002;26:227-35. http://dx.doi.org/10.1081/HEM- 120015026.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Eur J Haematol 2011;87:68-72. http://dx.doi.org/10.1111/j.1600- 0609.2011.01616.x.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Hemoglobin 2013;37:37-47. http://dx.doi.org/10.3109/03630269.2012.7 47964.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Eur J Haema- tol 2003;70:304-9. http://dx.doi.org/10.1034/j.1600-0609 .2003.00049.x.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Bailliére’s Clin Haematol  1994;7:787-804. http://dx.doi.org/10.1016/S0950-3536- (05)80124-6.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Biochemia Medica 2014;24(1):167–74  http://dx.doi.org/10.11613/BM.2014.019  174Singha K. et al.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Blo - od Cells Mol Dis 2006;37:8-11. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Acta Haematol 2011;125:186-92.  http://dx.doi.org/10.1159/000322666.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Ann Hema- tol 2009;88:535-43. http://dx.doi.org/10.1007/s00277-008- 0624-3.23.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Hemoglobin 2012;36:47-56. http://dx.doi.org/10.3109/03630269.2011.6 37149.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Br J Haematol 2006;133:98- 102. http://dx.doi.org/10.1111/j.1365-2141.2006.05971.x.,Non-OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
Blood Cells Mol Dis 2013;51:89-93. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c6/58/biochem-24-1-167-20.PMC3936978.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biochemia Medica 2014;24(1):6  http://dx.doi.org/10.11613/BM.2014.001  6Preanalytical Phase – an updated review of the current evidence Ana-Maria Simundic Editor-in-chief, Biochemia Medica, Zagreb, CroatiaEditorial European Federation of Clinical Chemistry and  Laboratory Medicine (EFLM) Working group for preanalytical phase (WG-PRE) has recently launched a series of conferences on preanalytical phase.",Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:25-30. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Bio - chem Med 2014;24:31-44. http://dx.doi.org/10.11613/BM.2014.006.,Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:45-56. http://dx.doi.org/10.11613/BM.2014.007.,Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:57-67. http://dx.doi.org/10.11613/BM.2014.008.,OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:68-79. http://dx.doi.org/10.11613/BM.2014.009.,OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:80-8. http://dx.doi.org/10.11613/BM.2014.010.,OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:89-104. http://dx.doi.org/10.11613/BM.2014.011.,Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:105-13. http://dx.doi.org/10.11613/BM.2014.012.,Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
Biochem Med 2014;24:114-22. http://dx.doi.org/10.11613/BM.2014.013.,Non-OADS,/arxiv_data1/oa_pdf/21/b0/biochem-24-1-6-2.PMC3936979.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Abstract In the 70ies of the last century, ther term “preanalytical phase” was introduced in the literature.",Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
"Key words: influence factors; interference factors; preanalytical factors; amylase in urine; haemolytic samples; anticoagulants; blood collection  tubes; centrifugation Received: October 29, 2013 Accepted: December 01, 2013 http://dx.doi.org/10.11613/BM.2014.005 Biochemia Medica 2014;24(1):25–30    25Review History of the preanalytical phase: a personal view Walter G. Guder Department of Clinical Chemistry, Munich Community Hospital (emerited), Munich, Germany Corresponding author: walter.guder@extern.lrz-muenchen.de Introduction The domain of medical laboratories is the perform - ance of diagnostic analysis.",Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Biochemia Medica 2014;24(1):25–30  http://dx.doi.org/10.11613/BM.2014.005  26Guder WG.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
http://dx.doi.org/10.11613/BM.2014.005 Biochemia Medica 2014;24(1):25–30    27Guder WG.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Biochemia Medica 2014;24(1):25–30  http://dx.doi.org/10.11613/BM.2014.005  28Guder WG.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
http://dx.doi.org/10.11613/BM.2014.005 Biochemia Medica 2014;24(1):25–30    29Guder WG.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Crit Rev Clin Lab Sci 1977;8:105-44. http://dx.doi.org/10.3109/10408367709151694.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Scand J Clin Lab Invest 1999;59:491-500. http://dx.doi.org/10.1080/00365519950185229.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Clin Chem Lab Med 2008;46:1189-94. http://dx.doi.org/10.1515/ CCLM.2008.225.,OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Biochemia Medica 2014;24(1):25–30  http://dx.doi.org/10.11613/BM.2014.005  30Guder WG.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
Lab Med 2003;34:304-10. http://dx.doi.org/10.1309/ JCQE33NBYGE0FFQR.,OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
D Med Wchschr 2009;134:575- 84. http://dx.doi.org/10.1055/s-0029-1208089.,Non-OADS,/arxiv_data1/oa_pdf/fb/65/biochem-24-1-25-6.PMC3936980.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Abstract Introduction : Serum blood collection tubes with separator gel are widely used by many laboratories for chemistry analyses.",Non-OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
"Key words : separator gel; preanalytical phase; blood collection tube; floating gel; hyperproteinemia Received: October 24, 2013 Accepted: January 15, 2014Abnormal gel flotation in a patient with apperant pneumonia diagnosis: a case  report Fethullah Gerin*, Dilber Coban Ramazan, Ozgur Baykan, Onder Sirikci, Goncagul Haklar Department of Biochemistry, School of Medicine, Marmara University, Istanbul, Turkey *Corresponding author: drfgerin@yahoo.comCase report Biochemia Medica 2014;24(1):180–2  http://dx.doi.org/10.11613/BM.2014.021  180 Introduction Serum blood collection tubes with separator gel  are widely used by many laboratories for chemis - try analyses due to the advantage of the barrier gel that facilitates quick and complete separation of serum from blood cells (1).",Non-OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
http://dx.doi.org/10.11613/BM.2014.021 Biochemia Medica 2014;24(1):180–2    181Gerin F. et al.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Biochemia Medica 2014;24(1):180–2  http://dx.doi.org/10.11613/BM.2014.021  182Gerin F. et al.,Non-OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Clin Chim Acta 2001;306:139-43. http://dx.doi.org/10.1016/S0009-8981(01)00396-5.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Clin Biochem 2010;43:4-25. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Clin Chim Acta 2012;413:100-4.  http://dx.doi.org/10.1016/j.cca.2011.08.037.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
J Clin Lab Anal 2012;26:246-7. http://dx.doi.org/10.1002/jcla.21512.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Clin Chem 2007;53:364-5. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
Ann Clin Biochem 2003;40:249-51. http://dx.doi.org/10.1258/000456303321610556.,Non-OADS,/arxiv_data1/oa_pdf/90/9c/biochem-24-1-180-22.PMC3936981.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.017 Biochemia Medica 2014;24(1):151–8    151Abstract Introduction : Congenital analbuminemia is a rare autosomal recessive disorder manifested by the presence of a very low amount of circulating  serum albumin.",Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochemia Medica 2014;24(1):151–8  http://dx.doi.org/10.11613/BM.2014.017  152Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
http://dx.doi.org/10.11613/BM.2014.017 Biochemia Medica 2014;24(1):151–8    153Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochemia Medica 2014;24(1):151–8  http://dx.doi.org/10.11613/BM.2014.017  154Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
http://dx.doi.org/10.11613/BM.2014.017 Biochemia Medica 2014;24(1):151–8    155Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochemia Medica 2014;24(1):151–8  http://dx.doi.org/10.11613/BM.2014.017  156Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
http://dx.doi.org/10.11613/BM.2014.017 Biochemia Medica 2014;24(1):151–8    157Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochemia Medica 2014;24(1):151–8  http://dx.doi.org/10.11613/BM.2014.017  158Caridi G. et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochim Biop - hys Acta 2013;1830:5494-502. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Hum Mutat 2008;29:1007-16. http://dx.doi.org/10.1002/humu.20754.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Eur J Clin Invest 2013;43:72-8. http://dx.doi.org/10.1111/eci.12019.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Lab Med 2004;35:350-6. http://dx.doi.org/10.1309/ CGE0XNNU2GKY2X2E .,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Nat Com-mun 2012;3:610. http://dx.doi.org/10.1038/ncomms1607.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochem J 2010;430:365-77. http://dx.doi.org/10.1042/BJ20100699.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Nuc-leic Acids Res 1982;10:459-72. http://dx.doi.org/10.1093/ nar/10.2.459.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Nucleic Acids Res 2006;34:4630-41. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Biochim Biop - hys Acta 2002;1586:43-9. http://dx.doi.org/10.1016/S0925- 4439(01)00084-9.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Clin Chem 2007;53:1549-52. http://dx.doi.org/10.1373/ clinchem.2007.089748.,Non-OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Clin Biochem 2012;45:1183-6. http://dx.doi.org/10.1016/j.clinbiochem.2012.05.007.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Mol Genet Metab 2012;105:479-83. http://dx.doi.org/10.1016/j.ymgme.2011.12.009.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
Clin Biochem 2010;43:525-7. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c5/d2/biochem-24-1-151-18.PMC3936982.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biochemia Medica 2014;24(1):146–50  http://dx.doi.org/10.11613/BM.2014.016  146Abstract Introduction : Sample type recommended by the manufacturer for the digoxin Abbott assay is either serum collected in glass tubes or plasma  (sodium heparin, lithium heparin, citrate, EDTA or oxalate as anticoagulant) collected in plastic tubes.",Non-OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
http://dx.doi.org/10.11613/BM.2014.016 Biochemia Medica 2014;24(1):146–50    147Dukić L. et al.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Biochemia Medica 2014;24(1):146–50  http://dx.doi.org/10.11613/BM.2014.016  148Dukić L. et al.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
http://dx.doi.org/10.11613/BM.2014.016 Biochemia Medica 2014;24(1):146–50    149Dukić L. et al.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Biochemia Medica 2014;24(1):146–50  http://dx.doi.org/10.11613/BM.2014.016  150Dukić L. et al.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Crit Care Clin 2012;28:527-35. http://dx.doi.org/10.1016/j.ccc.2012.07.005.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Pharm Weekbl [Sci] 1988;10:185-8. http://dx.doi.org/10.1007/BF01956868.,Non-OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Clin Chem Lab Med 2002;40:986-93. http://dx.doi.org/10.1515/ CCLM.2002.172.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Lancet 1986;1:307-10. http://dx.doi.org/10.1016/S0140- 6736(86)90837-8.,Non-OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Thromb Res  2007;119:133-4. http://dx.doi.org/10.1016/j.thromres.2005.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Clin Biochem 2010;43:4-25. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Bi-ochem Med 2012;22:180-6. http://dx.doi.org/10.11613/ BM.2012.021.,Non-OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Clin Chem Lab Med 2013;51:1043-51. http://dx.doi.org/10.1515/cclm-2012-0507.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
Clin Chem Lab Med 2004;42:67-71.  http://dx.doi.org/10.1515/CCLM.2004.013.,OADS,/arxiv_data1/oa_pdf/88/b6/biochem-24-1-146-17.PMC3936983.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    89Abstract Urine may be a waste product, but it contains an enormous amount of information.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  90Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis Patient preparation and sampling  procedures The laboratory is responsible for correct informa - tion regarding optimal patient preparation and  best sampling procedure.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    91Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis cytes was also observed between females and  males in first-voided samples, whereas no signifi - cant difference could be found in mid-stream sam - ples.",OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  92Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis flowcytometric erythrocyte count and the per - centage of nonlysed erythrocytes has been ob - served for urine samples with normal osmolality  (conductivity) in conventional and vacuum test  tubes.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    93Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis preservative gets too low, reducing the preserva - tive action.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  94Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis ciated with false negative strip test results (e.g.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    95Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis cific gravity and high urinary ascorbate concentra - tions [oral or parenteral intake of large doses of  ascorbic acid or vitamin C (2-15 g/day)] may de - crease the sensitivity of glucose oxidase (10,35).",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  96Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis and in vitro growth can result in false-positive re - actions, whereas a short bladder incubation time,  Gram-positive bacteria, vitamin C or no intake of  vegetables can give false-negative results (10).",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    97Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis comparison with bacterial cultures, the analytical  sensitivity for bacteria is poor at lower counts.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  98Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis (4,49).",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    99Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis terioration and protecting samples from tamper - ing.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  100Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis mate/glutamine, urea and lactate concentrations  decrease.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    101Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis Patient preparation Education of patients, general practioners and laboratory staff - Explaining effect of dietary intake, diuresis, exercise and other interferents - Illustrated sampling instructions - Washing glans penis of men and introitus of women - Use of soap or antiseptics is not recommended - Collection of specimens, preservation, transport and storage Routine urine samples for chemical, bacterial or particle analysis1 .",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  102Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis tion of vacuum systems has enabled swift trans - port of urine specimens and limits the risk of con - tamination and errors.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Am J Nep - hrol 1994;14:452-7. http://dx.doi.org/10.1159/000168764.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Bioche - mia Medica 2010;20:179-83. http://dx.doi.org/10.11613/ BM.2010.022.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Lab Med 2008;28:339-50. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"http://dx.doi.org/10.11613/BM.2014.011 Biochemia Medica 2014;24(1):89–104    103Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis  9.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Biochem Med 2013;23:316-20. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Bio - chem 2012;45:605-9. http://dx.doi.org/10.1016/j.clinbio - chem.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.clsi.org/.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Ann Rev Med 1968;19:431-70. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Scand J Clin Lab Invest 1997;57:203-8. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem Lab Med 2012;50:679-84. http://dx.doi.org/10.1515/ cclm.2011.823.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem 2009;55:24- 38. http://dx.doi.org/10.1373/clinchem.2008.106567.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Am J Kidney Dis 2008;51:1052-67. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Am J Clin Pathol 2013;140:306-13. http://dx.doi.org/10.1309/AJCP5ON9JHXVNQOD .24.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
J Clin Pathol 1999;52:95-8. http://dx.doi.org/10.1136/jcp.52.2.95.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem Lab Med 2008;46:703-13. http://dx.doi.org/10.1515/CCLM.2008.122.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Brit Med J 1969;2:353-5. http://dx.doi.org/10.1136/ bmj.2.5653.353.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
J Pediatr 1978;92:852-3. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Pediatr Clin N Am 2006;53:325-37. http://dx.doi.org/10.1016/j.pcl.2006.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
BMJ 1996;313:25. http://dx.doi.org/10.1136/ bmj.313.7048.25.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Scand J Clin Lab Invest 1980;40:259-61. http://dx.doi.org/10.3109/00365518009095576.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"Biochemia Medica 2014;24(1):89–104  http://dx.doi.org/10.11613/BM.2014.011  104Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis 43.",Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Lan-cet 1982;i:1432-4. http://dx.doi.org/10.1016/S0140-6736- (82)92451-5.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Nephron 1993;64:32-6. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem Lab Med 1998;36:935-9.  http://dx.doi.org/10.1515/CCLM.1998.162.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem Lab Med 1999;37:753-64. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chim Acta 2006;372:54-64. http://dx.doi.org/10.1016/j.cca.2006.03.015.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chim Acta 2007;384:28-34. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
J Clin Lab Anal 2013;27:312-6. http://dx.doi.org/10.1002/jcla.21604.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Clin Chem Lab Med 2011 49:999-1003. http://dx.doi.org/10.1515/ CCLM.2011.156.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.ncbi.nlm.nih.gov/books/ NBK64750/.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.clsi.org/.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.ewdts.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.gpo.gov/fdsys/pkg/FR-2004 -04-13/pdf/04-7984.pdf/ .,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Ava- ilable at: http://faculty.ksu.edu.sa/18856/454/AGSA%20 %20Drugs%20of%20Abuse%20Testing%20Guidelines.pdf.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.sai- global.com/pdftemp/previews/osh/as/as4000/4300/4308.pdf/.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Accred Qual Assur 2006; 11:284-90. http://dx.doi.org/10.1007/s00769-006-0131-y .,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
J Forensic Sci 2004;49:160-4. http://dx.doi.org/10.1520/JFS2003233.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Ther Drug Monit 2010;32:11-8. http://dx.doi.org/10.1097/ FTD.0b013e3181c0eee0.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
J Biomol NMR 2011;49:231-43. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Biopreserv Biobank 2010;8:65-9. http://dx.doi.org/10.1089/bio.2010.8102.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Nat Protoc 2007;2:2692-703. http://dx.doi.org/10.1038/nprot.2007.376.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Metabolomi-cs 2007;3:19-27. http://dx.doi.org/10.1007/s11306-006- 0042-2.,OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
Available at: http://www.iso-15189.com/.,Non-OADS,/arxiv_data1/oa_pdf/df/05/biochem-24-1-89-12.PMC3936984.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    31Abstract Improper design or use of blood collection devices can adversely affect the accuracy of laboratory test results.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  32Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    33Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  34Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    35Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  36Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    37Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  38Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    39Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  40Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    41Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
High Alt Med Bio 2008;9:235-7. http://dx.doi.org/10.1089/ham.2008.1027.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
J Clin Lab Anal 2008;22:391-4. http://dx.doi.org/10.1002/jcla.20277.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  42Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2005;51:424- 33. http://dx.doi.org/10.1373/clinchem.2004.043349.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Biomaterials 2004;25:5681-703. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Biomaterials 2009;30:1857-69. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Transfusion 2000;40:669-72. http://dx.doi.org/10.1046/j.1537-2995.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem Lab Med 2004;42:435-9. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
J Clin Microbiol 2001;39:354-6. http://dx.doi.org/10.1128/JCM.39.1.354-356.2001.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Lab Med 2003;34:732-5. http://dx.doi.org/10.1309/BMQHCD6B8984RLA3.23.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
AAPS PharmSciTe - ch 2010;11:1572-9. http://dx.doi.org/10.1208/s12249-010- 9531-8.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2004;50:2398- 401. http://dx.doi.org/10.1373/clinchem.2004.040303.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
J Lab Clin Med 2006;147:139-44. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"http://dx.doi.org/10.11613/BM.2014.006 Biochemia Medica 2014;24(1):31–44    43Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem Acta  2001;304:147-51. http://dx.doi.org/10.1016/S0009-8981- (00)00412-5.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chim Acta 2004;346:65-72.  http://dx.doi.org/10.1016/j.cccn.2004.02.035.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem Lab Med 2008;46:396-400. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Proteomics 2005;13:3414- 22. http://dx.doi.org/10.1002/pmic.200401219.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Am J Clin Pathol 2000;113:429-52. http://dx.doi.org/10.1309/C0NM-Q7R0-LL2E-B3UY .,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Ann Clin Biochem 2013; 50:3-5. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2003;49:1187-9. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2008;54:771-2. http://dx.doi.org/10.1373/clinchem.2007.093716.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Ther Drug Mo - nit 1990;12:277-80. http://dx.doi.org/10.1097/00007691- 199005000-00011.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem Lab Med 2009;47:358-61. http://dx.doi.org/10.1515/ CCLM.2009.072.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin  Chim Acta 2012;413:1454-8. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin  Biochem 2012;45:1706-9. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem Lab Med 2010;48:651-7. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Steroids 2008;73:1345-52. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2006;52:2115-6. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Arterioscler Thromb Vasc Biol 2008;28:611-14. http://dx.doi.org/10.1161/ATVBAHA.107.159608.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
"Biochemia Medica 2014;24(1):31–44  http://dx.doi.org/10.11613/BM.2014.006  44Bowen RAR, Remaley AT.",Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2013;25:833-45. http://dx.doi.org/10.1373/ clinchem.2012.199257.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chim Acta 2007;378:181-93. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chem 2008;54:1608-16. http://dx.doi.org/10.1373/ clinchem.2008.108175.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Semin Thromb Hemost 2001;27:349-56. http://dx.doi.org/10.1055/s-2001-16888.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Biochem 2001;34:107-12.  http://dx.doi.org/10.1016/S0009-9120(01)00196-5.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Pharmacol Rev 2008;60:470- 512. http://dx.doi.org/10.1124/pr.108.000604.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Proteomics 2005;5:3262-77. http://dx.doi.org/10.1002/pmic.200401245 .,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Thromb Res 2005;116:249-54. http://dx.doi.org/10.1016/j.thromres.2004.12.005.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Chim Acta 1998;274:111-17. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Am J Clin Pathol 2006;126:174-84. http://dx.doi.org/10.1309/3WM7XJ7RD8BCLNKX .,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Biochem Med 2012;22:180-6. http://dx.doi.org/10.11613/BM.2012.021.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Ann Saudi Med 2011;31:223-28. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Biochem Med 2010; 20: 207-14. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Clin Biochem 2010;43:4-25. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/3e/biochem-24-1-31-7.PMC3936985.pdf
Two months after publication it is available to  the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Cre - ative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/00/3e/549.PMC3937082.pdf
"I foresee enormous progress on this front in a very short  time, 2–3 years, as many of the 6000–8000 rare inherited diseases  (http://raregenomics.org/) yield information on the gene affected by  the causal mutation.",Non-OADS,/arxiv_data1/oa_pdf/00/3e/549.PMC3937082.pdf
Available at http://www.fao.org/wsfs/   forum2050/en/.,Non-OADS,/arxiv_data1/oa_pdf/00/3e/549.PMC3937082.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/05/17/554.PMC3937083.pdf
"According to the software  PredictNLS (https://rostlab.org/owiki/index.php/PredictNLS), CHES1  possesses a nuclear localization signal (NLS) in the C-terminal do - main between residues 418 and 445 (Figure 2A).",OADS,/arxiv_data1/oa_pdf/05/17/554.PMC3937083.pdf
"To study the mechanism of PIM2  repression by CHES1, we mapped  potential forkhead binding sites along the PIM2  promoter from −2.5  to +0.25 of the transcription start site with the Transcriptional Regu - latory Element Database (http://rulai.cshl.edu/cgi-bin/TRED/tred   .cgi?process =home), using the HNF3- β/FOXA2 matrix (Figure 5A  and Supplemental Table S1).",OADS,/arxiv_data1/oa_pdf/05/17/554.PMC3937083.pdf
(A) Identification of potential forkhead binding sites along the PIM2  promoter according to the Transcriptional Regulatory Element Database (http://rulai.cshl.edu/cgi-bin/TRED/tred   .cgi?process =home).,Non-OADS,/arxiv_data1/oa_pdf/05/17/554.PMC3937083.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/1b/c8/566.PMC3937084.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/37/24/583.PMC3937085.pdf
The sequence information of V2  dsRNA is available at http://rnai.ucsf.edu/mitoscreendb/general   .php?tablename =Drosophila %20genes&num_p_r =12&gen_curr   _page=0&user=guest&pwd =guest&javascript_enabled =true.,OADS,/arxiv_data1/oa_pdf/37/24/583.PMC3937085.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/24/f6/594.PMC3937086.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/8b/a7/606.PMC3937087.pdf
Two months after publication it is  available to the public under an Attribution–Noncommercial–Share Alike 3.0 Un - ported Creative Commons License (http://creativecommons.org/licenses/by-nc- sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/cf/a4/620.PMC3937088.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/e4/9e/633.PMC3937089.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/2d/c9/643.PMC3937090.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/b9/15/658.PMC3937091.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/37/7a/669.PMC3937092.pdf
"After se - quencing, the data sets were sorted by barcode using a Python  script available on our website (https://reck-peterson.med.harvard   .edu/protocols).",OADS,/arxiv_data1/oa_pdf/37/7a/669.PMC3937092.pdf
"We wrote scripts in Unix to navigate be - tween BWA, SAMtools, and GATK (https://reck-peterson.med   .harvard.edu/protocols).",OADS,/arxiv_data1/oa_pdf/37/7a/669.PMC3937092.pdf
"A Python script (https://reck-peterson.med   .harvard.edu/protocols) was used to identify and remove synony - mous mutations, as well as nucleotide changes common to the non - mutagenized parent strains, progeny with the phenotype, and prog - eny lacking the phenotype.",OADS,/arxiv_data1/oa_pdf/37/7a/669.PMC3937092.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/0b/09/679.PMC3937093.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/d1/22/688.PMC3937094.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/e6/94/702.PMC3937095.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/fc/f7/712.PMC3937096.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2014:9 239–246International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  239RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S5751 1A review of halotherapy for chronic obstructive  pulmonary disease Rachael Rashleigh1 Sheree MS Smith1,2 Nicola J Roberts3 1Family and Community Health  University Research Group, School  of Nursing and Midwifery, University  of western Sydney, Campbelltown  Campus, Sydney, NSw , Australia;   2Centre for Pharmacology  and Therapeutics, Division of  experimental Medicine, Imperial  College, South Kensington, London,   United Kingdom; 3Institute of Applied  Health Research, School of Health  and Life Sciences, Glasgow Caledonian  University, Glasgow, Scotland Correspondence: Rachael Rashleigh   Family and Community Health   University Research Group, School   of Nursing and Midwifery, University  of western Sydney, Locked Bag 1797,  Penrith, NSw 2751, Australia   Tel +61 2 4620 3532   Fax +61 2 4620 3199   email rachael@rashleigh.com.a uBackground:  Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease  and is treated with inhaled medication to optimize the patient’ s lung health through decreasing  their symptoms, especially breathlessness.",Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://guidance.nice.org.uk/CG10 1.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://www.goldcopd.org/ guidelines-global-strategy-for-diagnosis-management.htm l.  6.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://au.news.yahoo.com/ today-tonight/latest/article/-/12487174/ancient-treatment-revamped /.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
"Available from: http://aca.ninemsn.com.au/article/8472866/   salt-therap y. Accessed January 17, 2013.",Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://aca.ninemsn.com.au/article.aspx?id =822281 1.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://aca.ninemsn.com.au/article.aspx?id =8280493.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://au.news.yahoo.com/today-tonight/health/ article/-/7892980/salt-rooms /.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from:  http://edition.cnn.com/2009/HEALTH/06/23/salt.cave.uk/.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://www.nbcnews.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Available from: http://www.sign.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/31/6a/copd-9-239.PMC3937102.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/20/31/cia-9-357.PMC3937103.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 357–367Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  357RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S4425 9Treatment options and outcomes for   glioblastoma in the elderly patient Nils D Arvold1 David A Reardon2 1Department of Radiation Oncology,   Dana-Farber/Brigham and women’s  Cancer Center, Boston, MA, USA;   2Center for Neuro-Oncology, Dana- Farber/Brigham and women’s Cancer  Center, Boston, MA, USA Correspondence: Nils D Arvold   Department of Radiation Oncology,  Brigham and women’s Hospital,   ASB1 Level L2, 75 Francis St, Boston,   MA 02215, USA   Tel +1 617 732 6313 ext 3   Fax +1 617 975 0932   email narvold@partners.or gAbstract:  Age remains the most powerful prognostic factor among glioblastoma (GBM)  patients.",Non-OADS,/arxiv_data1/oa_pdf/20/31/cia-9-357.PMC3937103.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/20/31/cia-9-357.PMC3937103.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/20/31/cia-9-357.PMC3937103.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1e/d8/ccide-6-015.PMC3937104.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical, Cosmetic and Investigational Dentistry 2014:6 15–19Clinical, Cosmetic and Investigational Dentistry Dove press submit your manuscript | www.dovepress.co m Dove press  15OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CCIDE.S5929 2Clinical study of the safety and effectiveness   of a novel over-the-counter bleaching tray system K Michael ghalili1 Kamal Khawaled2 Doran rozen2 Veda afsahi3 1Department of Prosthodontics, new  Y ork University College of Dentistry,   new Y ork, nY, Usa; 2Department of  r&D; Department of Clinical affairs,   syneron Beaut y, ltd, Y okneam, Israel;    3Veda Faith afsahi Inc., Fountain   Valley, C a, Usa Correspondence: K Michael ghalili   65 West 55th street, suite 305,   new York, nY 10019, Usa   Tel +1 212 581 5360   email kghalili@gmail.co mAbstract:  We investigated color change, gingival irritation, and tooth sensitivity in patients  undergoing at-home vital tooth bleaching with a novel over-the-counter bleaching tray system.",Non-OADS,/arxiv_data1/oa_pdf/1e/d8/ccide-6-015.PMC3937104.pdf
"Clinical, Cosmetic and Investigational Dentistry Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-cosmetic-and-investigational-dentistry-journa lClinical, Cosmetic and Investigational Dentistry is an international,  peer-reviewed, open access, online journal focusing on the latest clini - cal and experimental research in dentistry with specific emphasis on  cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/1e/d8/ccide-6-015.PMC3937104.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/1e/d8/ccide-6-015.PMC3937104.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0b/7f/copd-9-229.PMC3937108.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2014:9 229–238International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  229RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S3893 2Bacterial microbiome of lungs in COPD Marc A Sze1 James C Hogg2 Don D Sin1 1Department of Medicine,   2Department of Pathology and  Laboratory Medicine, The James Hogg  Research Centre, Providence Heart- Lung Institute, St Paul’s Hospital,   University of British Columbia,   vancouver, BC, Canada Correspondence : Don D Sin   UBC James Hogg Research Centre,  Providence Heart-Lung Institute, St Paul’s  Hospital, Room 166, 1081 Burrard Street,   vancouver, BC, Canada v6Z 1Y6   Tel +1 604 806 8346 ext 68395   Fax +1 604 806 8351   email don.sin@hli.ubc.c aAbstract : Chronic obstructive pulmonary disease (COPD) is currently the third leading cause  of death in the world.",Non-OADS,/arxiv_data1/oa_pdf/0b/7f/copd-9-229.PMC3937108.pdf
Available  from: http://www.who.int/healthinfo/ global_burden_disease /2004_ report_update/en /.,Non-OADS,/arxiv_data1/oa_pdf/0b/7f/copd-9-229.PMC3937108.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/0b/7f/copd-9-229.PMC3937108.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0b/7f/copd-9-229.PMC3937108.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e2/ff/copd-9-247.PMC3937109.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/e2/ff/copd-9-247.PMC3937109.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/ff/copd-9-247.PMC3937109.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 369–376Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  369Methodologyopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/ 10.2147/CIA.S5393 1does progressive resistance and balance exercise  reduce falls in residential aged care?,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Available from: http://www.abs.gov.au/ausstats/abs@.nsf/ mf/3236.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Available from: http://www.mbsonline.gov.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Available from: http://www.pbs.gov.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
Available from:   http://www.health.gov.au/internet/main/publishing.nsf/Content/ Round_14-cost-reports.,Non-OADS,/arxiv_data1/oa_pdf/76/36/cia-9-369.PMC3937111.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/77/f6/ceor-6-101.PMC3937113.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinicoEconomics and Outcomes Research 2014:6 101–108ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  101ORiginal RESEaRCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S5702 8The cost of antiretroviral treatment service   for patients with HiV/aiDS in a central   outpatient clinic in Vietnam long Thanh nguyen1  Bach Xuan Tran2 Cuong T uan Tran1 Huong Thi le1 Son Van Tran1 1authority of HiV/ aiDS Control,   Ministry of Health, Hanoi, Vietnam;   2institute for Preventive Medicine  and Public Health, Hanoi Medical  University, Hanoi, Vietnam Correspondence: Bach Xuan Tran  institute for Preventive Medicine and  Public Health, Hanoi Medical University,   no 1, T on That T ung, Hanoi, Vietnam   Tel +84 98 222 8662   Email bach@hmu.edu.v nIntroduction:  Antiretroviral treatment (ART) services are estimated to account for 30% of  the total resources needed for human immunodeficiency virus (HIV)/acquired  immunodeficiency  syndrome (AIDS) control and prevention in Vietnam during the 2011–2020 timeframe.",Non-OADS,/arxiv_data1/oa_pdf/77/f6/ceor-6-101.PMC3937113.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/77/f6/ceor-6-101.PMC3937113.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/77/f6/ceor-6-101.PMC3937113.pdf
"Available at http://www.unaids.org/en/media/ unaids/contentassets/dataimport/pub/report/2008/20080603_nasa_  indonesia_06_07_en.pd f. Accessed May 1, 2013.7.",Non-OADS,/arxiv_data1/oa_pdf/77/f6/ceor-6-101.PMC3937113.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/29/e5/jmdh-7-123.PMC3937182.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Multidisciplinary Healthcare 2014:7 123–127Journal of Multidisciplinary Healthcare Dove press submit your manuscript | www.dovepress.co m Dove press  123ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/JMDH.S4691 0Feasibility of a self-administered survey   to identify primary care patients at risk   of medication-related problems Mark J Makowsky1 Andrew J Cave2 Scot H Simpson1 1Faculty of Pharmacy and  Pharmaceutical Sciences, 2Department  of Family Medicine, Faculty of  Medicine and Dentistry, University   of Alberta, Edmonton, AB, Canada Correspondence : Andrew J Cave   Department of Family Medicine,   Faculty of Medicine and Dentistry,  University of Alberta, 901 College Plaza,  Edmonton, AB T6G 2R3, Canada   Tel +1 780 492 8102   Fax +1 780 492 2593   Email andrew.cave@ualberta.c aBackground and objectives:  Pharmacists working in primary care clinics are well positioned  to help optimize medication management of community-dwelling patients who are at high  risk of experiencing medication-related problems.",Non-OADS,/arxiv_data1/oa_pdf/29/e5/jmdh-7-123.PMC3937182.pdf
"Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journa lThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research  in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/29/e5/jmdh-7-123.PMC3937182.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/29/e5/jmdh-7-123.PMC3937182.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpStem Cells and Cloning: Advances and Applications 2014:7 31–44Stem Cells and Cloning: Advances and Applications Dove press submit your manuscript | www.dovepress.co m Dove press  31Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ SCCAA.S3800 3Brain repair: cell therapy in stroke Dheeraj Kalladka Keith w Muir institute of Neuroscience and  Psychology, University of Glasgow,   Southern General Hospital, Glasgow,   United Kingdom Correspondence: Dheeraj Kalladka   institute of Neuroscience and Psychology,   University of Glasgow, Southern General   Hospital, Glasgow, United Kingdom   Tel +44 141 201 2144   Fax +44 141 201 2136   email dheeraj.kalladka@glasgow.ac.u kAbstract:  Stroke affects one in every six people worldwide, and is the leading cause of adult  disability.",Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
"Stem Cells and Cloning: Advances and Applications 2014:7submit your manuscript | www.dovepress.co m Dove press Dove press 36Kalladka and MuirTable 1  Clinical trials listed on http://www.clinicaltrials.go v (as of August 5, 2013) Location   (trial acronym)Subjects Controls Cell type Study   PhaseTime from   stroke onsetDelivery   modeDose   (×105)Primary   outcomeSecondary   outcomeID Completion   date Neural stem cells (NSCs) Glasgow, UK   (PiSCeS)10612 No Allogeneic NSC:   CTX0e03i 6 mo to 5 y ST 200 Ae mRS, NiHSS, Bi,   eQ-5DTMNCT01151124 Mar 2014 Mesenchymal stem cells (MSCs) Rio de Janeiro,   Brazil13112 No Autologous BMSC i ,90 d iv, iA 5,000 Ae imaging NCT00473057 May 2011 Manipal Acunova,   india132120 Yes: no   interventionAutologous BMSC ii 7 to 30 d iv 5,000 Bi NiHSS, mRS NCT01501773 Oct 2011 San Diego, CA,   USA10735 No Allogeneic BMSC i/ii .6 mo iv 1,050 Ae NiHSS, MMSe, Bi,   GDSNCT01297413 May 2013 Pune, india   (BMACS)13350 No Autologous BMSC i, ii NA intrathecal   (3 divided   doses)1,000 improvement of   body and facial   musclesimprovement in   speech, walking,   or visionNCT01832428 Mar 2014 Malaysia13450 Yes: no   interventionAutologous BMSC ii 1 wk to 2 mo iv NA mRS, NiHSS, Bi SiS, QOL NCT01461720 Mar 2014 Aldagen, USA148100 Yes: placebo Autologous BMSC   (ALD-401)ii 13 to 19 d iA (carotid) NA Ae mRS, NiHSS, Bi,   eQ-5DTMNCT01273337 Dec 2014 irvine, CA, USA13540 Yes:   placeboBMSC i, ii ,3 d iv NA Ae Efficacy NCT01849887 Jan 2015 People’s Republic   of China13630 Yes: no   interventionAutologous BMSC i NA intracerebral 40 NiHSS MRi infarct size NCT01714167 Dec 2015 Samsung Medical   Centre, Korea137  (STARTiNG-2)60 Yes: no  interventionMSC iii ,90 d iv NA mRS Clinical: mRS,   NiHSS, Bi, eQ-5DTM  Blood: CSF – SDF,   S100b, HiF, CD105- CXCR4, BDNF, veGF.",Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01151124.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01297413?term =NCT01297413&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/ show/NCT01501773?term=NCT01501773&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT0183 2428?term=NCT01832428&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
A vailable from:  http://clinicaltrials.gov/ct2/show/NCT01461720?term=NCT0146172 0&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/show/ NCT01849887.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/ show/NCT01716481?term=NCT01716481&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT00875654?t erm=NCT00875654&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available  from: http://clinicaltrials.gov/ct2/show/NCT00761982?term=NCT007 61982&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT00535197?term =NCT00535197&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
"Stem Cells and Cloning: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journa lStem Cells and Cloning: Advances and Applications is an international,  peer-reviewed, open access journal.",Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01310114?term =NCT01310114&rank=1.,OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
A vailable from:  http://clinicaltrials.gov/ct2/show/NCT01453829?term=NCT0145382 9&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01678 534?term=NCT01678534&rank=1.NLM identifier: NCT0167853 4.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT00859014?term =NCT00859014&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Avail - able from: http://clinicaltrials.gov/ct2/show/NCT01438593?term= NCT01438593&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01436487?term =NCT01436487&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT0127 3337?term=NCT01273337&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT01287936?term =NCT01287936&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/e7/d8/sccaa-7-031.PMC3937183.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ad/3a/ijn-9-1065.PMC3937184.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 1065–1082International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1065OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5486 4Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/ad/3a/ijn-9-1065.PMC3937184.pdf
"Or use: http://dvpr.es/1hosTx KIn vivo enhancement of anticancer therapy   using bare or chemotherapeutic drug-bearing   nanodiamond particles Yingqi li1,2 Yaoli T ong1 ruixia cao1 Zhimei Tian2 Binsheng Yang2 Pin Yang2 1Department of chemistry, college of  chemistry and chemical engineering,   2Key laboratory of chemical Biology  and Molecular engineering of Ministry  of education, Institute of Molecular  science, shanxi University, Taiyuan,   People’s republic of china correspondence: Yingqi li; Binsheng Yang   Key laboratory of chemical Biology   and Molecular engineering of Ministry of   education, Institute of Molecular science,   shanxi University, Taiyuan 030006,   People’s republic of china   Tel +86 35 1701 0588   email wkyqli@sxu.edu.c n; yangbs@sxu.",Non-OADS,/arxiv_data1/oa_pdf/ad/3a/ijn-9-1065.PMC3937184.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/ad/3a/ijn-9-1065.PMC3937184.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/3a/ijn-9-1065.PMC3937184.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/de/4b/ott-7-333.PMC3937185.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 333–342OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  333Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S3464 1Isotype-specific inhibition of the  phosphatidylinositol-3-kinase pathway   in hematologic malignancies Jorge J Castillo1 Meera iyengar2 Benjamin Kuritzky2 Kenneth D Bishop2 1Division of Hematologic Malignancies,   Dana-Farber Cancer Institute, Boston,   MA, 2Division of Hematology and  Oncology, Rhode Island Hospital,   Providence, RI, USA Correspondence: Jorge J Castillo   450 Brookline Ave, M221,   Boston, MA 02215, USA   Tel +1 617 632 6285   Fax +1 617 632 6482   email jorgej_castillo@dfci.harvard.ed uAbstract:  In the last decade, the advent of biological targeted therapies has revolutionized the  management of several types of cancer, especially in the realm of hematologic malignancies.",Non-OADS,/arxiv_data1/oa_pdf/de/4b/ott-7-333.PMC3937185.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/de/4b/ott-7-333.PMC3937185.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/de/4b/ott-7-333.PMC3937185.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cc/29/opth-8-429.PMC3937186.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 429–433Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  429Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/OPTH.S5808 7In vivo laser confocal microscopy findings   of a cornea with osteogenesis imperfecta akira Kobayashi tomomi Higashide Hideaki Y okogawa Natsuko Yamazaki toshinori Masaki Kazuhisa sugiyama Department of Ophthalmology,   Kanazawa University Graduate school  of Medical science, Kanazawa, Japan Correspondence: akira Kobayashi   Department of Ophthalmology,  Kanazawa University Graduate school  of Medical science, 13-1 takara-machi,  Kanazawa, Ishikawa-prefecture   920-8641, Japan   tel +81 76 265 2403   Fax +81 76 222 9660   email kobaya@kenroku.kanazawa-u.ac.j pObjective:  To report the in vivo laser confocal microscopy findings of a cornea with   osteogenesis imperfecta (OI) with special attention to the abnormality of Bowman’ s layer and  sub-Bowman’ s fibrous structures (K-structures).",Non-OADS,/arxiv_data1/oa_pdf/cc/29/opth-8-429.PMC3937186.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/cc/29/opth-8-429.PMC3937186.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/29/opth-8-429.PMC3937186.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/a3/ijn-9-1097.PMC3937187.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 1097–1104International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1097OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5849 9a reusable localized surface plasmon resonance  biosensor for quantitative detection of serum  squamous cell carcinoma antigen in cervical cancer  patients based on silver nanoparticles array Qianying Zhao1 ruiqi Duan1 Jialing Yuan1 Yi Quan1 huan Yang2 Mingrong Xi1 1Department of gynecology and  Obstetrics, West china second  University hospital, sichuan  University, 2state Key laboratory  of Optical T echnologies for Micro- fabrication, Institute of Optics and  electronics, chinese academy of  science, chengdu, sichuan, People’s  republic of china correspondence: Mingrong Xi   Department of gynecology and  Obstetrics, West china second  University hospital, sichuan University,  chengdu, china.",Non-OADS,/arxiv_data1/oa_pdf/c0/a3/ijn-9-1097.PMC3937187.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/c0/a3/ijn-9-1097.PMC3937187.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/a3/ijn-9-1097.PMC3937187.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cc/a2/ijn-9-1039.PMC3937188.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 1039–1048International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1039OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5827 0Subtype classification for prediction of prognosis  of breast cancer from a biomarker panel:  correlations and indications Chuang Chen1 Jing-Ping Yuan2,3 Wen Wei1 Yi T u1 Feng Yao1 Xue-Qin Yang4 Jin-Zhong Sun1 Sheng-Rong Sun1 Yan Li2 1Department of Breast and Thyroid  Surgery, Wuhan University, Renmin  hospital, Wuhan, 2Department of  Oncology, Zhongnan Hospital of  Wuhan University and Hubei Key  Laboratory of Tumor Biological  Behaviors and hubei cancer clinical  study center, Wuhan, 3Department  of Pathology, The Central Hospital  of Wuhan, Wuhan, 4Medical school  of Jingchu University of T echnology,   Jingmen, People’s Republic of China Correspondence: Sheng-Rong Sun   Department of Breast and Thyroid  Surgery, Wuhan University, Renmin  Hospital, 99 Ziyang Road, Wuchang  District, Wuhan, hubei 430060,   People’s Republic of China   email sun137@sina.co m    Yan Li   Department of Oncology, Zhongnan  Hospital of Wuhan University and Hubei  Key Laboratory of T umor Biological  Behaviors, 169 Donghu Road, Wuchang  District, Wuhan, 430071,   People’s Republic of China   T el +86 27 6781 3152   Fax +86 27 6781 2892   email liyansd2@163.co mBackground:  Hormone receptors, including the estrogen receptor and progesterone receptor, human  epidermal growth factor receptor 2 (HER2), and other biomarkers like Ki67, epidermal growth  factor receptor (EGFR, also known as HER1), the androgen receptor, and p53, are key molecules  in breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/cc/a2/ijn-9-1039.PMC3937188.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/cc/a2/ijn-9-1039.PMC3937188.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/a2/ijn-9-1039.PMC3937188.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fd/2f/ijn-9-1083.PMC3937189.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 1083–1096International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1083OrIg INal rESEarCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5977 9Epithelial cell adhesion molecule aptamer  functionalized Plga-lecithin-curcumin-PEg  nanoparticles for targeted drug delivery to   human colorectal adenocarcinoma cells lei li1,* Dongxi Xiang2,* Sarah Shigdar2 Wenrong Yang3 Qiong li2 Jia lin4 Kexin liu1 Wei Duan2 1College of Pharmacy, Dalian Medical  University, Dalian, People’s republic  of China; 2School of Medicine, Faculty  of Health, Deakin University, Waurn  Ponds, VIC, australia; 3School of life  and Environmental Sciences, Faculty  of Science, Engineering and Built  Environment, Deakin University,   Waurn Ponds, VIC, australia;   4Department of Biochemistry and  Molecular Biology, West China School  of Preclinical and Forensic Medicine,   Sichuan University, Chengdu, People’s  republic of China  *These authors contributed equally   to this work Correspondence: Dongxi Xiang   School of Medicine, Deakin University,   75 Pigdons roads, Waurn Ponds, Victoria  3217, australia   Tel +61 4 5256 5738   Email dxiang@deakin.edu.a u    Wei Duan   School of Medicine, Deakin University,   75 Pigdons roads, Waurn Ponds, Victoria  3217, australia   Tel +61 3 5227 1149   Fax +61 3 5227 2945   Email wduan@deakin.edu.a uAbstract:  To improve the efficacy of drug delivery, active targeted nanotechnology-based drug  delivery systems are gaining considerable attention as they have the potential to reduce side  effects, minimize toxicity, and improve efficacy of anticancer treatment.",Non-OADS,/arxiv_data1/oa_pdf/fd/2f/ijn-9-1083.PMC3937189.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/fd/2f/ijn-9-1083.PMC3937189.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fd/2f/ijn-9-1083.PMC3937189.pdf
"OncoImmunology 2013; 2:e27255; http://dx.doi.org/10.4161/onci.27255Targeting human CD27 with   an agonist antibody stimulates T-cell activation  and antitumor immunity Lawrence J Thomas1, Li-Zhen h e2, henry Marsh1, and Tibor Keler2,* 1Celldex Therapeutics, Inc.; Needham, M a usa ; 2Celldex Therapeutics, Inc.; Phillipsburg, NJ usa Keywords:  CD27, co-stimulation, Fc receptors, immunotherapy, monoclonal antibody Abbreviations: FcR, Fc receptor; hCD27-Tg, human CD27 transgenic; IFN, interferon; TCR, T-cell receptor CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
Clin Cancer Res 2012;  18:3812-21;  PMID:22589397 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
J Immunol 2013; 191:4174-83; PMID:24026078 ;  http://dx.doi.org/10.4049/jimmunol.1300409 5.,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
PLoS  One 2008; 3:e1708; http://dx.doi.org/10.1371/jour - nal.pone.0001708 ; PMID:183200297.,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
Cancer Res 2012; 72:3664-76; PMID:22628427 ; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2791 8.,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
Int J Cancer 2006; 118:1728- 35; PMID:16217761 ; http://dx.doi.org/10.1002/ ijc.215449.,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
Biochem Biophys  Res Commun 2010; 393:829-35; PMID:20171165 ;  http://dx.doi.org/10.1016/j.bbrc.2010.02.092 10.,OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
J Immunother 2010; 33:769-79; PMID:20842060 ; http://dx.doi.org/10.1097/ CJI.0b013e3181ee238f,Non-OADS,/arxiv_data1/oa_pdf/eb/e6/onci-3-e27255.PMC3937191.pdf
OncoImmunology 2014; 3:e27817;  http://dx.doi.org/10.4161/onci.27817,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
N Engl J Med 2012; 366:2443- 54 PMID:22658127http://dx.doi.org/10.1056/ NEJMoa1200690 3.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nat Rev Cancer  2012 ; 12:252-64 PMID:22437870http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Clin Cancer Res 2012 ; 18:6580 -7  PMID:23087408http://dx.doi.org/10.1158/1078-0432.CCR-12-1362 9.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nature  2013 ; 499:214-8  PMID:23770567http://dx.doi.org/10.1038/nature12213 10.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nature   2013 ; 500:415-21 PMID:23945592http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Clin Vaccine Immunol 2011 ; 18:23- 34 PMID:21048000http://dx.doi.org/10.1128/ CVI.00286-10 13.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Cancer Immunol Immunother  2011 ;  60:1137 -46 PMID:21465316http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Proc Natl Acad Sci USA 2011 ;  108:16723 -8 PMID:21933959http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
J Clin Oncol  2013 ; 31:e439 -42 PMID:24043743http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nat Methods  2009 ;  6:520-6 PMID:19543285http://dx.doi.org/10.1038/ nmeth.1345,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nat Protoc  2012 ;  7:891-902 PMID:22498709http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Cancer Res 2012 ; 72:1081 -91  PMID:22237626http://dx.doi.org/10.1158/0008- 5472.CAN-11-3722 19.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Mutat Res  2005 ; 571:19- 31 PMID:15748635http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Nature   2010 ; 463:184-90 PMID:20016488http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Cell  2012 ; 150:1121 -34 PMID:22980976http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Semin Cancer  Biol 2012 ; 22:23-32 PMID:22210181http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Mutat Res  2005 ; 571:185- 205 PMID:15748647http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
Sci Transl Med 2012 ; 4:127ra37 ;  PMID:22461641 ; http://dx.doi.org/10.1126/ scitranslmed.3003689,Non-OADS,/arxiv_data1/oa_pdf/cb/d4/onci-3-e27817.PMC3937193.pdf
"OncoImmunology 2014; 3:e27048;  http://dx.doi.org/10.4161/onci.27048Trial Watch Tumor-targeting monoclonal antibodies in cancer therapy erika v acchelli1,2,3,4,†, Fernando a randa1,2,3,†, alexander e ggermont1, Jérôme Galon5,6,7, 8, Catherine Sautès-Fridman6,7,9,   Laurence Zitvogel1,10, Guido Kroemer2,3,5,11,12,‡,* and Lorenzo Galluzzi1,3,5,‡,* 1Gustave r oussy; v illejuif, France; 2INSerM, U848; v illejuif, France; 3equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de r echerche des Cordeliers;   Paris, France; 4Université Paris-Sud/Paris XI; Paris, France; 5Université Paris Descartes/Paris v ; Sorbonne Paris Cité; Paris, France; 6Université Pierre et Marie Curie/Paris v I;   Paris, France; 7INSerM, U872; Paris, France; 8equipe 15, Centre de r echerche des Cordeliers; Paris, France; 9equipe 13, Centre de r echerche des Cordeliers; Paris, France;  10INSerM, U1015; CICBT507; v illejuif, France; 11Pôle de Biologie; Hôpital e uropéen Georges Pompidou; a P-HP; Paris, France; 12Metabolomics and Cell Biology Platforms;   Gustave r oussy; v illejuif, France †These authors contributed equally to this work ‡These authors share senior co-authorship Keywords:  bevacizumab, brentuximab vedotin, cetuximab, nimotuzumab, trastuzumab, tumor-associated antigen Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis;  CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukemia; CRC, colorectal carcinoma; DLBCL, diffuse  large B-cell lymphoma; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; EPCAM, epithelial cell  adhesion molecule; FDA, Food and Drug Administration; HNSCC, head and neck squamous cell carcinoma; IGF1R, insulin-like  growth factor 1 receptor; IL, interleukin; mAb, monoclonal antibody; MMAE, monomethyl auristatin E; NHL, non-Hodgkin’s  lymphoma; NSCLC, non-small cell lung carcinoma; TAA, tumor-associated antigen; TNF α, tumor necrosis factor α ; VEGF,  vascular endothelial growth factor In 1997, for the first time in history, a monoclonal antibody  (mab), i.e., the chimeric anti-CD20 molecule rituximab, was  approved by the US Food and Drug a dministration for use  in cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"46,47 Finally, no earlier than on 2013, September  30th, the US FDA granted accelerated approval to pertuzumab (a humanized IgG1 specific for HER2) for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2 +, locally advanced, inflammatory, or  early-stage breast cancer.48 Of note, pertuzumab had previously  (on 2012, June 8th) been licensed for use in combination with trastuzumab and docetaxel for the treatment of patients with metastatic HER2 + breast carcinoma who have not received prior  anti-HER2 therapy or chemotherapy for metastatic disease.49  However, the recent regulatory extension granted to this tumor-targeting mAB is relevant as pertuzumab in combination with trastuzumab and docetaxel has now become the first FDA-approved neoadjuvant treatment for patients with breast cancer (source http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm).",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Narrowing down the search to “antibody AND cancer AND patients AND trial” resulted in approximately 600 entries (source http://www.ncbi.nlm.nih.gov/pubmed).,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"e27048-10 OncoImmunology volume 3 November 18th, the US FDA revoked the authorization that was  given to bevacizumab for use in metastatic breast cancer patients (in combination with paclitaxel) in February 2008 (which was originally granted under the FDA accelerated approval program) (source http://www.cancer.gov/cancertopics/druginfo).",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"Among a huge amount of preclinical studies demonstrating the efficacy of tumor-targeting mAbs in a large panel of experimental paradigms (source http://www.ncbi.nlm.nih.gov/pubmed), we have found of particular interest the work by Boross and colleagues, demonstrating that IgAs and the corresponding Fc receptor (CD89) may be harnessed to achieve robust antineoplastic effects in vivo.",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"Update on Clinical Trials Testing Tumor-Targeting  Monoclonal Antibodies When this Trial Watch was being redacted (October 2013),  official sources listed 74 clinical trials launched after 2012, October 1st to evaluate the therapeutic profile of hitherto investigational tumor-targeting mAbs in cancer patients (16 studies) or the efficacy of FDA-approved tumor-targeting mAbs employed as off-label anticancer interventions (58 studies) (source http://www.clinicaltrials.gov).",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"Among “Active, not recruiting” and “Completed” studies, (preliminary or definitive) results appear to be available for NCT00560794; 241 NCT00778167; NCT00838201;  NCT00848926; NCT00866047; NCT00947856;242 and  NCT00986674 (source http://www.clinicaltrials.gov).",Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Immunol 2004 ; 4:153-6; PMID:15040588 ;  http://dx.doi.org/10.1038/nri1265 3.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Immunol 2010 ; 10:317- 27; PMID:20414205 ; http://dx.doi.org/10.1038/ nri2744 4.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  Pract  1998 ; 6:195-7; PMID:9652253 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e22789 ;  PMID:23482847 ; http://dx.doi.org/10.4161/ onci.22789 6.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2012 ; 1:28-37; PMID:22720209 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e24238 ;  PMID:23762803 ; http://dx.doi.org/10.4161/ onci.24238 8.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e23510 ;  PMID:23687621 ; http://dx.doi.org/10.4161/ onci.23510 9.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e23803 ;  PMID:23734328 ; http://dx.doi.org/10.4161/ onci.23803 10.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Drug Discov 2012 ; 11:215-33;  PMID:22301798 ; http://dx.doi.org/10.1038/ nrd3626 13.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:1223 -5; PMID:23243584 ;  http://dx.doi.org/10.4161/onci.21335 14.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:1197 -9; PMID:23170278 ;  http://dx.doi.org/10.4161/onci.2068715.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2013 ; 2:e24436 ; PMID:23762809 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Clin Oncol 2011 ; 8:151-60;  PMID:21364688 ; http://dx.doi.org/10.1038/ nrclinonc.2010.223 17.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ;  2:e24052 ; PMID:23762793 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res  2008 ; 14:502-8; PMID:18223225 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e24677 ;  PMID:23894722 ; http://dx.doi.org/10.4161/ onci.24677 20.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Immunity   2006 ; 24:19-28; PMID:16413920 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:103- 5; PMID:22720225 ; http://dx.doi.org/10.4161/ onci.1.1.17963 23.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:957-8; PMID:23162770 ;  http://dx.doi.org/10.4161/onci.19974 24.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:810-21; PMID:23162748 ;  http://dx.doi.org/10.4161/onci.20447 25.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Front Biosci (Landmark Ed)  2011 ; 16:277-306; PMID:21196171 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cell  Res 2010 ; 20:34-50; PMID :20010915 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med  2002 ; 346:235-42; PMID:11807147 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:75-7; PMID:22720216 ;  http://dx.doi.org/10.4161/onci.1.1.17825 31.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Cancer 2011 ; 2:309- 16; PMID:21716847 ; http://dx.doi.org/10.7150/ jca.2.309 32.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e22620 ;  PMID:23482411 ; http://dx.doi.org/10.4161/ onci.22620 33.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol  2002 ; 20:2453 -63; PMID:12011122 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:1445 -7; PMID:23243624 ;  http://dx.doi.org/10.4161/onci.21318 37.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Int J Cancer  2007 ; 120:781-7; PMID:17096332 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res  2013 ; 19:1858 -72; PMID:23444227 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:29- 37; PMID:23168366 ; http://dx.doi.org/10.1016/ S1470-2045(12)70477-1 40.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2007 ; 25:1539 - 44; PMID:17442997 ; http://dx.doi.org/10.1200/ JCO.2006.09.6305 41.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med 2007 ;  357:2666 -76; PMID:18160686 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med 2004 ; 350:2335 - 42; PMID :15175435 ; http://dx.doi.org/10.1056/ NEJMoa032691 43.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol   2013 ; 14:901-8; PMID:23867211 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Clin Oncol  2011 ; 9:76-8; PMID:22182971 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e24567 ;  PMID:23802090 ; http://dx.doi.org/10.4161/ onci.24567 48.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol   2012 ; 13:25-32; PMID :22153890 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med 2012 ; 366:109-19;  PMID:22149875 ; http://dx.doi.org/10.1056/ NEJMoa111321650.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med 2003 ; 349:2184 - 6; PMID:14657423 ; http://dx.doi.org/10.1056/ NEJMp038156 51.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Mol Cancer Ther 2009 ; 8:1095 -105;  PMID:19366899 ; http://dx.doi.org/10.1158/1535- 7163.MCT-08-1171 52.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Expert Opin  Investig Drugs  2009 ; 18:1025 -33; PMID:19548856 ;  http://dx.doi.org/10.1517/13543780903055049 53.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2009 ; 15:5445 -56;  PMID:19706799 ; http://dx.doi.org/10.1158/1078- 0432.CCR-08-2980 54.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer 2009 ; 100:366-9;  PMID:19165200 ; http://dx.doi.org/10.1038/ sj.bjc.6604839 55.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N Engl J Med 2007 ; 356:2271 - 81; PMID:17538086 ; http://dx.doi.org/10.1056/ NEJMoa066838 56.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:371-82; PMID:23477833 ;  http://dx.doi.org/10.1016/S1470-2045(13)70049-4 57.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol  2012 ; 23:2834 - 42; PMID:22700995 ; http://dx.doi.org/10.1093/ annonc/mds142 58.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:228-35; PMID:23414585 ;  http://dx.doi.org/10.1016/S1470-2045(13)70026-3 59.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Eur J Cancer  2013 ; 49:1799 -807; PMID:23485230 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2011 ; 17:6052 -60; PMID:21750201 ;  http://dx.doi.org/10.1158/1078-0432.CCR-10-2979 62.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncogene  2007 ; 26:3745 -57; PMID:17530027 ;  http://dx.doi.org/10.1038/sj.onc.1210374 63.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Adv Cancer Res  2009 ; 103:43-73; PMID:19854352 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  2013 ; 119:4290 - 8; PMID:24122767 ; http://dx.doi.org/10.1002/ cncr.28353 66.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2012 ; 30:4141 -7; PMID:23071222 ;  http://dx.doi.org/10.1200/JCO.2012.44.1055 67.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Invest 2012 ; 30:727-31;  PMID:23061802 ; http://dx.doi.org/10.3109/07357 907.2012.732163 68.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother Pharmacol  2011 ; 68:733- 41; PMID :21161528 ; http://dx.doi.org/10.1007/ s00280-010-1544-1 69.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2010 ; 16:5883 -91; PMID:20947515 ;  http://dx.doi.org/10.1158/1078-0432.CCR-10-0631 70.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2010 ;  16:1256 -63; PMID:20145186 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2011 ;  17:3181-92; PMID:21385927 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol  2010 ; 21:376- 81; PMID:19633048 ; http://dx.doi.org/10.1093/ annonc/mdp292 73.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Lett 2007 ; 251:146-57;  PMID:17184908 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet  2013 ;Forthcoming ;  PMID:24094768 ; http://dx.doi.org/10.1016/ S0140-6736(13)61719-5 77.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Mol Immunol  2012 ; 51:227- 33; PMID:22487721 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res  2010 ; 16:3044 -56; PMID:20501621 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2009 ; 27:3557 - 65; PMID:19546406 ; http://dx.doi.org/10.1200/ JCO.2008.19.6683 83.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2010 ; 16:699-710; PMID:20068101 ;  http://dx.doi.org/10.1158/1078-0432.CCR-09-1365 84.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2007 ; 13:6735 -42; PMID:18006775 ;  http://dx.doi.org/10.1158/1078-0432.CCR-06-2969 85.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Pharm Res  2007 ; 24:1910 -8; PMID:17520181 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother  Pharmacol  2013 ; 71:1041 -50; PMID:23385782 ;  http://dx.doi.org/10.1007/s00280-013-2099-8 87.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother Pharmacol  2013 ; 71:227-35;  PMID:23124648 ; http://dx.doi.org/10.1007/ s00280-012-2000-1 88.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Annu Rev Immunol 2013 ; 31:51-72;  PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008 90.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:179- 88; PMID:22720239 ; http://dx.doi.org/10.4161/ onci.1.2.19026 91.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res  2013 ; 19:215-24; PMID:23136195 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
OncoImmunology  2013 ; 2:e26084 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Blood  2013 ; 121:476- 84; PMID:23212516 ; http://dx.doi.org/10.1182/ blood-2012-08-450585 94.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Immunol  Immunother  2012 ; 61:2367 -73; PMID:23090290 ;  http://dx.doi.org/10.1007/s00262-012-1362-x 95.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol  2013 ; 24:1792 -801; PMID:23448807 ;  http://dx.doi.org/10.1093/annonc/mdt066 96.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Blood  2012 ; 120:5185 -7; PMID:23024237 ;  http://dx.doi.org/10.1182/blood-2012-07-441030 97.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol   2013 ; 129:452-8; PMID:23474348 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2013 ; 19:920-8; PMID:23362325 ;  http://dx.doi.org/10.1158/1078-0432.CCR-12-2616 99.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2013 ; 31:573-83;  PMID:23295790 ; http://dx.doi.org/10.1200/ JCO.2012.42.7211 100.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2013 ; 24:329-36; PMID:23104724 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Eur J Cancer 2013 ; 49:1169 -75; PMID:23294608 ;  http://dx.doi.org/10.1016/j.ejca.2012.11.033 102.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lung Cancer 2013 ; 79:270-5; PMID:23261229 ;  http://dx.doi.org/10.1016/j.lungcan.2012.11.017,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Sci 2013 ; 104:105- 10; PMID:23046388 ; http://dx.doi.org/10.1111/ cas.12040 104.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Lung Cancer 2012 ; 13:432-41;  PMID:22609229 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:461-71;  PMID:23602601 ; http://dx.doi.org/10.1016/ S1470-2045(13)70130-X 107.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Haematologica  2013 ; 98:119-28; PMID:22801961 ;  http://dx.doi.org/10.3324/haematol.2012.066613 109.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ;  1:1469 -75; PMID:23264893 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ;  2:e25595 ; PMID:24319634 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2013 ; 2:e24850 ; PMID:24073369 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2012 ; 1:493-506; PMID:22754768 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e24964 ;  PMID:24073376 ; http://dx.doi.org/10.4161/ onci.24964 114.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Immunother  2011 ;  34:611-28; PMID:21989410 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res  2011 ; 17:4091 -100; PMID :21527562 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Mol Cancer Ther  2011 ; 10:1072 -81; PMID:21467164 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Cancer Res  Clin Oncol  2013 ; 139:447-55; PMID:23160853 ;  http://dx.doi.org/10.1007/s00432-012-1327-7 121.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Blood  2012 ; 120:4706 - 11; PMID:23047822 ; http://dx.doi.org/10.1182/ blood-2012-04-420596 122.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  2013 ; 119:339-47;  PMID:22811009 ; http://dx.doi.org/10.1002/ cncr.27745 123.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer   2012 ; 118:5008 -14; PMID:22415650 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2013 ; 24:220-5; PMID:22898037 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer  2013 ; 108:1052 -60; PMID:23422754 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother Pharmacol  2013 ; 71:1051 - 7; PMID:23377310 ; http://dx.doi.org/10.1007/ s00280-013-2100-6 127.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Breast Cancer 2012 ;  12:322-30; PMID:23040000 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Eur J Cancer 2012 ; 48:3140 - 9; PMID:22640829 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  2013 ; 119:586-92; PMID :22915053 ;  http://dx.doi.org/10.1002/cncr.27760 132 .,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Eur J Cancer 2013 ; 49:999-1008 ; PMID:23265712 ;  http://dx.doi.org/10.1016/j.ejca.2012.11.008 133.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Am J Clin Oncol 2013 ; 36:254-7; PMID:22643560 ;  http://dx.doi.org/10.1097/COC.0b013e318248d83f 134.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncology   2013 ; 85:44-52; PMID:23838576 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Invest New Drugs 2012 ; 30:2384 - 90; PMID:22402942 ; http://dx.doi.org/10.1007/ s10637-012-9808-8,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  2013 ; 119:1042 - 9; PMID:23132335 ; http://dx.doi.org/10.1002/ cncr.27859 137.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2012 ; 23:2812 -20; PMID:22767582 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol  2013 ; 130:19-24; PMID:23623830 ;  http://dx.doi.org/10.1016/j.ygyno.2013.04.049 139.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol  2013 ; 129:459-62; PMID:23474345 ;  http://dx.doi.org/10.1016/j.ygyno.2013.02.035 140.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Int J  Gynecol Cancer  2013 ; 23:355-60; PMID:23358182 ;  http://dx.doi.org/10.1097/IGC.0b013e31827de69e 141.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:236- 43; PMID:23333117 ; http://dx.doi.org/10.1016/ S1470-2045(12)70567-3 142.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol  2013 ; 128:221-8; PMID:22960352 ;  http://dx.doi.org/10.1016/j.ygyno.2012.08.039 143.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol  2012 ; 23:3104 - 10; PMID:22851407 ; http://dx.doi.org/10.1093/ annonc/mds172 144.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer  2012 ; 118:4777 - 84; PMID:22282219 ; http://dx.doi.org/10.1002/ cncr.27416 145.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer 2013 ; 108:2549 -56; PMID:23703247;  http://dx.doi.org/10.1038/bjc.2013.245146.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Pediatr Blood Cancer   2013 ; 60:1447- 51; PMID :23630159 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol   2013 ; 130:64-8; PMID:23591400 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother  Pharmacol  2013 ; 71:955-63; PMID:23377373 ;  http://dx.doi.org/10.1007/s00280-013-2088-y 149.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2013 ; 31:724- 30; PMID:23341513 ; http://dx.doi.org/10.1200/ JCO.2012.42.5215 150.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Gynecol Oncol  2013 ; 129:22-7; PMID:23262204 ;  http://dx.doi.org/10.1016/j.ygyno.2012.12.022 151.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2013 ; 19:236-46; PMID:23143218 ;  http://dx.doi.org/10.1158/1078-0432.CCR-12-1897 152.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2013 ; 24:702-9; PMID:23108952 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2012 ; 18:5796 -805;  PMID:22927482 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-1158 154.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2013 ; 24:257-63; PMID:22910841 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Nucl Med 2013 ; 54:1014 - 8; PMID:23651946 ; http://dx.doi.org/10.2967/ jnumed.112.117218156.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2013 ; 31:1719 -25;  PMID:23569311 ; http://dx.doi.org/10.1200/ JCO.2012.44.7912 157.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol  2011 ; 29:4286 -93; PMID:21990397 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2011 ; 29:1252 -60;  PMID:21383283 ; http://dx.doi.org/10.1200/ JCO.2010.28.0982 159.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2013 ; 31:1219 - 30; PMID:23401453 ; http://dx.doi.org/10.1200/ JCO.2012.46.2762 160.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cell Rep  2012 ; 2:257- 69; PMID:22854025 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncogene   2012 ; 31:1869 -83; PMID:21892204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Res 2010 ;  70:1793 -803; PMID :20145152 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N  Engl J Med 2011 ; 365:2484 -96;  PMID:22204725 ;  http://dx.doi.org/10.1056/NEJMoa1103799 164.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Blood   2008 ; 111:2170 -80; PMID:17925489 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Res 2007 ; 67:6253 -62; PMID:17616683 ;  http://dx.doi.org/10.1158/0008-5472.CAN-07-0538 166.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2013 ; 31:2586 -92;  PMID:23733761 ; http://dx.doi.org/10.1200/ JCO.2012.46.2408,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Sci  2012 ; 103:1979 -84; PMID:22845557 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol   2013 ; 14:490-9; PMID:23594786 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Oncol   2012 ; 23:2820 -7; PMID:22571859 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Am J Clin Oncol 2012 ; 35:446-50;  PMID:21552097 ; http://dx.doi.org/10.1097/ COC.0b013e31821862fb 174.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Invest New Drugs 2013 ; 31:85-91;  PMID:22367239 ; http://dx.doi.org/10.1007/ s10637-012-9802-1 175.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother Pharmacol  2013 ; 71:1473 - 83; PMID :23589315 ; http://dx.doi.org/10.1007/ s00280-013-2146-5 176.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2012 ; 18:6049 -57;  PMID:22977195 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2219177.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2012 ; 30:3545 - 51; PMID:22927525 ; http://dx.doi.org/10.1200/ JCO.2012.41.9572 179.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Am  J Clin Oncol 2013 ; 36:77-82; PMID:22237145 ;  http://dx.doi.org/10.1097/COC.0b013e31823a4970 180.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2012 ;  13:1234 -41; PMID :23153506 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Thorac Oncol 2012 ; 7:1823 -9;  PMID:23154554 ; http://dx.doi.org/10.1097/ JTO.0b013e31826aec2b 182.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:697- 710; PMID:23746666 ; http://dx.doi.org/10.1016/ S1470-2045(13)70181-5 183.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Int J  Gynecol Cancer  2013 ; 23:73-80; PMID:23211422 ;  http://dx.doi.org/10.1097/IGC.0b013e3182775fae 184.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2012 ; 18:5752 -60;  PMID:22893631 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-0456 185.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2013 ; 14:481- 9; PMID:23594787 ; http://dx.doi.org/10.1016/ S1470-2045(13)70096-2186.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Jpn J Clin Oncol  2013 ; 43:466-75; PMID:23456745 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2008 ; 14:1296 -302; PMID:18316547 ;  http://dx.doi.org/10.1158/1078-0432.CCR-07-1354 188.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2009 ; 27:672-80; PMID:19114685 ;  http://dx.doi.org/10.1200/JCO.2008.19.8135 189.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2008 ; 26:1626 - 34; PMID:18316791 ; http://dx.doi.org/10.1200/ JCO.2007.14.7116 190.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2012 ; 30:1594 - 600; PMID:22393084 ; http://dx.doi.org/10.1200/ JCO.2011.37.4207 191.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
EMBO Mol Med  2013 ; 5:1213 - 26; PMID:23918228 ; http://dx.doi.org/10.1002/ emmm.201201929 192.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Chemother Pharmacol  2011 ; 67:837- 45; PMID:20563810 ; http://dx.doi.org/10.1007/ s00280-010-1379-9 193.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lung Cancer 2011 ; 71:55-9; PMID:20451284 ;  http://dx.doi.org/10.1016/j.lungcan.2010.04.010 194.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Cancer Res 2010 ; 16:1915 -23; PMID:20197484 ;  http://dx.doi.org/10.1158/1078-0432.CCR-09-2425,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Biol Ther 2012 ; 13:600-5; PMID:22555809 ;  http://dx.doi.org/10.4161/cbt.19849 200.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Invest  New Drugs  2011 ; 29:996-1003 ; PMID:20454832 ;  http://dx.doi.org/10.1007/s10637-010-9444-0 204.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Invest New Drugs 2012 ;  30:1585 -90; PMID:21901403 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Exp Cell Res 2011 ; 317:1255 -60;  PMID:21419116 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2011 ; 29:2493 -8; PMID:21576633 ;  http://dx.doi.org/10.1200/JCO.2010.32.7270 211.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Immunother Emphasis Tumor Immunol  1996 ; 19:206-17; PMID:8811495 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
N  Engl J Med 2010 ; 363:1324 -34; PMID:20879881 ;  http://dx.doi.org/10.1056/NEJMoa0911123 214.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
BMC Cancer  2011 ; 11:21; PMID:21244693 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e23402 ;  PMID:23802080 ; http://dx.doi.org/10.4161/ onci.23402 216.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:477-86;  PMID:22754766 ; http://dx.doi.org/10.4161/ onci.19864 217.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2013 ; 19:3914 -24;  PMID:23729364 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-3814 218.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Cancer Res 2013 ; 19:1784 -94;  PMID:23403634 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2518219.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Leuk Lymphoma   2009 ; 50:1336 -44; PMID:19557623 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Mol Med  2013 ; 19:99- 108; PMID:23615966 ; http://dx.doi.org/10.2119/ molmed.2013.00009 222.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
OncoImmunology  2013 ; 2: e26494 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Radiology  2008 ; 246:497- 507; PMID:18227543 ; http://dx.doi.org/10.1148/ radiol.2462070229 224.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer  2013 ; 109:934-42; PMID:23860529 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Rev Drug Discov 2012 ; 11:19-20;  PMID:22212672 ; http://dx.doi.org/10.1038/ nrd3629 227.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Nat Biotechnol  2012 ; 30:631- 7; PMID:22781692 ; http://dx.doi.org/10.1038/ nbt.2289 228 .,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer Cell  2012 ; 21:459-72;  PMID:22516257 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Pract Neurol  2011 ; 11:160-6;  PMID:21551110 ; http://dx.doi.org/10.1136/ practneurol-2011-000017 231.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2010 ; 28:3525 -30;  PMID:20458041 ; http://dx.doi.org/10.1200/ JCO.2010.27.9836 233.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
J Clin Oncol 2010 ; 28:1749 - 55; PMID:20194866 ; http://dx.doi.org/10.1200/ JCO.2009.25.3187 234.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Cancer   2009 ; 115:859-68; PMID:19140204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Ann Hematol 2002 ; 81:26-32;  PMID:11807632 ; http://dx.doi.org/10.1007/ s00277-001-0394-7 236.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin Lymphoma  2002 ; 3:26- 35; PMID:12141952 ; http://dx.doi.org/10.3816/ CLM.2002.n.008 237.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Clin  Colorectal Cancer  2006 ; 6:29-31; PMID:16796788 ;  http://dx.doi.org/10.3816/CCC.2006.n.01 238.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Lancet Oncol  2006 ; 7:370;  PMID:16696165 ; http://dx.doi.org/10.1016/ S1470-2045(06)70681-7239.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer 2010 ; 103:1154 - 62; PMID:20808314 ; http://dx.doi.org/10.1038/ sj.bjc.6605872 240.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J  Haematol  2011 ; 152:579-92; PMID:21241278 ;  http://dx.doi.org/10.1111/j.1365-2141.2010.08533.x 241.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Blood   2012 ; 119:6226 -33; PMID:22592608 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2012 ; 1:699-716; PMID:22934262 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2012 ; 1:894-907;  PMID:23162757 ; http://dx.doi.org/10.4161/ onci.20931245.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology  2013 ; 2:e25238 ;  PMID:24083080 ; http://dx.doi.org/10.4161/ onci.25238 246.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Immunity  2013 ; 38:729- 41; PMID:23562161 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Oncoimmunology   2013 ; 2:e22409 ; PMID:23482968 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Science   2012 ; 337:1678 -84; PMID:23019653 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
Br J Cancer 2013 ; 108:826-30; PMID:23412108 ;  http://dx.doi.org/10.1038/bjc.2013.46,Non-OADS,/arxiv_data1/oa_pdf/ea/cc/onci-3-e27048.PMC3937194.pdf
"Biotechnol J 2011; 6:700-6; PMID:21567964; http://dx.doi.org/10.1002/biot.201100146.Keywords:  Pichia pastoris , membrane  proteins, protein production, high-resolu - tion structures, aquaporin, GPCR Abbreviations:  GPCR, G protein- coupled receptor; GFP, green fluorescent  protein; AQP, aquaporin Submitted: 11/28/12Revised: 02/04/13Accepted: 02/04/13http://dx.doi.org/10.4161/bioe.23886 Correspondence to: Kristina Hedfalk;   Email: kristina.hedfalk@chem.gu.seMembrane proteins have essential  cellular functions and are there - fore of high interest in both academia and industry.",OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
"3 Notably, P. pastoris   is the most common yeast host among the 383 eukaryotic membrane proteins structures reported at 4 Å or lower (http://blanco.biomol.uci.edu/mpstruc/listAll/list).",Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
"To date, there are high resolution structures for 15 mem - bers of this protein family whereof all but one is a result of recombinant production (http://blanco.biomol.uci.edu/mpstruc/listAll/list).",Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Biotechnol  J 2011; 6:700-6; PMID:21567964; http://dx.doi.org/10.1002/biot.201100146.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
J Cell Mol Med 2007; 11:224-38; PMID:17488474; http://dx.doi.org/10.1111/j.1582-4934.2007.00028.x.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nat Biotechnol 2011; 29:335-40; PMID:21478852; http://dx.doi.org/10.1038/nbt.1833.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
FEBS Lett 2001; 504:94-8; PMID:11532439; http://dx.doi.org/10.1016/S0014-5793(01)02711-9.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Protein Sci 2005; 14:1729-40; PMID:15987902; http://dx.doi.org/10.1110/ps.051435705.6.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Mol Membr Biol 2011; 28:398-411; PMID:21770695; http://dx.doi.org/10.3109/09687688.2011.602219.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Protein  Expr Purif 2002; 24:212-20; PMID:11858715; http://dx.doi.org/10.1006/prep.2001.1564.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Mol  Membr Biol 2009; 26:215-27; PMID:19384754; http://dx.doi.org/10.1080/09687680902862085.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
J Appl Microbiol  2001; 90:397-406; PMID:11298235; http://dx.doi.org/10.1046/j.1365-2672.2001.01259.x.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Protein Expr  Purif 2009; 68:7-11; PMID:19545633; http://dx.doi.org/10.1016/j.pep.2009.06.013.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2009; 323:1718-22; PMID:19325113; http://dx.doi.org/10.1126/science.1168750.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2012;  335:436-41; PMID:22282805; http://dx.doi.org/10.1126/science.1213808.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2011; 474:521-5; PMID:21593763; http://dx.doi.org/10.1038/nature10136.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2011; 469:241- 4; PMID:21228877; http://dx.doi.org/10.1038/nature09746.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nat Protoc  2008; 3:784-98; PMID:18451787; http://dx.doi.org/10.1038/nprot.2008.44.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Mol Membr Biol 2013; 30:15-31; PMID:22908994; http://dx.doi.org/10.3109/09687688.2012.665503.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Methods Mol Biol 2012; 866:65-73; PMID:22454115; http://dx.doi.org/10.1007/978-1-61779-770-5_7.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Curr Opin Biotechnol 2001; 12:28-34; PMID:11167069; http://dx.doi.org/10.1016/S0958-1669(00)00171-3.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nat Biotechnol 2009; 27:561-6; PMID:19465926; http://dx.doi.org/10.1038/nbt.1544.26.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2012; 335:432-6; PMID:22282804; http://dx.doi.org/10.1126/science.1213274.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2011; 475:65-70; PMID:21697825; http://dx.doi.org/10.1038/nature10236.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science  2009; 326:1668-74; PMID:20019282; http://dx.doi.org/10.1126/science.1180310.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2010; 328:67-73; PMID:20360102; http://dx.doi.org/10.1126/sci - ence.1185954.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2006; 439:688-94; PMID:16340961; http://dx.doi.org/10.1038/nature04316.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Cell 2011; 147:199-208; PMID:21962516; http://dx.doi.org/10.1016/j.cell.2011.07.046.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nat Rev Drug Discov 2006; 5:993-6; PMID:17139284; http://dx.doi.org/10.1038/nrd2199.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Med Sci (Paris) 2012; 28:876-82; PMID:23067420; http://dx.doi.org/10.1051/med-sci/20122810017.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
J Mol Biol 2011; 409:298-310; PMID:21501622; http://dx.doi.org/10.1016/j.jmb.2011.03.075.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
PLoS Biol 2009; 7:e1000130; PMID:19529756; http://dx.doi.org/10.1371/journal.pbio.1000130.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2011; 477:495-8; PMID:21874019; http://dx.doi.org/10.1038/nature10370.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2012; 338:1308-13; PMID:23180775; http://dx.doi.org/10.1126/science.1228757.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2012; 490:566-9; PMID:23000902; http://dx.doi.org/10.1038/nature11448.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Science 2005; 309:897-903;  PMID:16002581; http://dx.doi.org/10.1126/sci - ence.1116269.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2007; 450:376-82; PMID:18004376; http://dx.doi.org/10.1038/nature06265.,OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
Nature 2007; 448:613-6; PMID:17632546; http://dx.doi.org/10.1038/nature06009.,Non-OADS,/arxiv_data1/oa_pdf/05/85/bbug-4-363.PMC3937196.pdf
"Bioengineered 4:6, 368–373; November/December 2013; © 2013 Landes Bioscience Comme Ntary 368 Bioengineered  Volume 4 Issue 6Keywords:  elastin-like proteins, extracel - lular matrix, surface-coatings, hydrogels,  drug and gene delivery, regenerative medicine Submitted: 01/06/13Revised: 02/25/13Accepted: 02/28/13http://dx.doi.org/10.4161/bioe.24158 Correspondence to: Won Bae Jeon;   Email: wbjeon@dgist.ac.kr With the remarkable increase in  the fields of biomedical engineer - ing and regenerative medicine, biomate - rial design has become an indispensable approach for developing the biocompat - ible carriers for drug or gene cargo and extracellular matrix (ECM) for cell sur - vival, proliferation, and differentiation.",Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
BMC Biotechnol 2012; 12:61; PMID:22978264; http://dx.doi.org/10.1186/1472-6750-12-61,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Adv Biochem Eng Biotechnol 2011; 125:145-79; PMID:21072696; http://dx.doi.org/10.1007/10_2010_94.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Control Release 2010; 144:2-9; PMID:20117157; http://dx.doi.org/10.1016/j.jconrel.2010.01.032.4.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Invest New Drugs 2007; 25:313-26; PMID:17483874; http://dx.doi.org/10.1007/s10637-007-9053-8.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Control Release 2011; 155:175-83; PMID:21846483; http://dx.doi.org/10.1016/j.jconrel.2011.07.040.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Cancer Lett 2012; 319:136-43; PMID:22261328; http://dx.doi.org/10.1016/j.can - let.2011.12.042.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Control Release 2008; 129:179-86; PMID:18547669; http://dx.doi.org/10.1016/j.jcon - rel.2008.04.021.8.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Control Release 2011; 155:144-51; PMID:21763734; http://dx.doi.org/10.1016/j.jcon - rel.2011.06.044.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Control Release 2011; 155:218-26; PMID:21699930; http://dx.doi.org/10.1016/j.jconrel.2011.06.010.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Pharm Res 2008; 25:683-91; PMID:17762916; http://dx.doi.org/10.1007/s11095-007-9382-5.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Med Hypotheses 2011; 76:239-40; PMID:21041034; http://dx.doi.org/10.1016/j.mehy.2010.10.007.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Biomed Mater Res A 2011; 97:152-7; PMID:21370445; http://dx.doi.org/10.1002/jbm.a.33041.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
BMC Biotechnol 2012; 12:61; PMID:22978264; http://dx.doi.org/10.1186/1472-6750-12-61.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2012; 9:5111-21; PMID:23085563; http://dx.doi.org/10.1016/j.act - bio.2012.10.016.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Small 2011; 7:2640-9; PMID:21809443; http://dx.doi.org/10.1002/smll.201100875.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomaterials 2008; 29:625-32; PMID:18006054; http://dx.doi.org/10.1016/j.bio - materials.2007.10.022.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biotechnol Bioeng 2011; 108:1171-80; PMID:21449029; http://dx.doi.org/10.1002/bit.23025.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2013; 9:5600-8; PMID:23142478; http://dx.doi.org/10.1016/j.act - bio.2012.10.036.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomaterials 2012; 33:515-23; PMID:22018385; http://dx.doi.org/10.1016/j.biomaterials.2011.09.070.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Mater Chem 2012; 22:19429-37; PMID:23015764; http://dx.doi.org/10.1039/c2jm31768k.23.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Biomed Mater Res A 2011; 97:243-50; PMID:21442725; http://dx.doi.org/10.1002/jbm.a.33050.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2008; 4:827-37; PMID:18178532; http://dx.doi.org/10.1016/j.actbio.2007.11.004.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Nanoscale Res Lett 2009; 4:1247-53; PMID:20596391; http://dx.doi.org/10.1007/s11671-009-9388-5.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Small 2011; 7:2640-9; PMID:21809443; http://dx.doi.org/10.1002/smll.201100875.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Macromol Rapid Commun 2011; 32:186-90; PMID:21433138; http://dx.doi.org/10.1002/marc.201000491.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Mater Sci Mater Med 2004; 15:479-84; PMID:15332621; http://dx.doi.org/10.1023/B:JMSM.0000021124.58688.7a.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomacromolecules 2008; 9:222-30; PMID:18163573; http://dx.doi.org/10.1021/bm7007982.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Tissue Eng Part A 2008; 14:1133-40; PMID:18433311; http://dx.doi.org/10.1089/ten.tea.2007.0245.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2013; 9:5590-9; PMID:23128159; http://dx.doi.org/10.1016/j.actbio.2012.10.033.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2010; 6:2108-15; PMID:20026437; http://dx.doi.org/10.1016/j.actbio.2009.12.034.33.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomacromolecules 2003; 4:572-80; PMID:12741772; http://dx.doi.org/10.1021/bm025671z.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Acta Biomater 2012; 8:988-97; PMID:22154858; http://dx.doi.org/10.1016/j.actbio.2011.11.024.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Tissue Eng 2005; 11:1768-79; PMID:16411822; http://dx.doi.org/10.1089/ten.2005.11.1768.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Enzyme Microb Technol 2011; 49:347-52; PMID:22112559; http://dx.doi.org/10.1016/j.enzmictec.2011.06.012.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
J Mater Sci Mater Med 2011; 22:2641-50; PMID:21993611; http://dx.doi.org/10.1007/s10856-011-4451-z.,Non-OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomacromolecules 2012; 13:2315-21; PMID:22789001; http://dx.doi.org/10.1021/bm300760s.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Soft Matter 2012; 8:10141-8; PMID:23226161; http://dx.doi.org/10.1039/c2sm26082d.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Biomaterials 2006; 27:91-9; PMID:16023192; http://dx.doi.org/10.1016/j.bio - materials.2005.05.071.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Adv Drug Deliv Rev 2010; 62:1479-85; PMID:20385185; http://dx.doi.org/10.1016/j.addr.2010.04.002.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Nat Biotechnol 2005; 23:862-71; PMID:16003375; http://dx.doi.org/10.1038/nbt1119.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
Tissue Eng Part B Rev 2012; 18:116-28; PMID:22010760; http://dx.doi.org/10.1089/ten.teb.2011.0498.,OADS,/arxiv_data1/oa_pdf/9c/88/bbug-4-368.PMC3937197.pdf
"www.landesbioscience.com  Bioengineered  401Bioengineered 4:6, 401–407; Nov ember/December 2013; © 2013 Landes Bioscience Resea Rch pape R Resea Rch pape R *Correspondence to: Roy D Sleator; Email: roy.sleator@cit.ie Submitted: 01/11/13; Revised: 02/21/13; Accepted: 02/24/13http://dx.doi.org/10.4161/bioe.24094Introduction A characteristic feature of the intracellular foodborne pathogen  Listeria monocytogenes  is its ability to thrive in a variety of stress - ful environments.1,2 This phenotypic robustness can be attributed  at least in part to the ability of the organism to accumulate a vari - ety of protective compounds, termed compatible solutes, which help to buffer the cell from the detrimental effects of a range of environmental insults.",Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Int Dairy J 2001; 12:273-83; http://dx.doi.orggvb/10.1016/S0958-6946(01)00125-X.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Microbiology 2009; 155:2463-75; PMID:19542009; http://dx.doi.org/10.1099/mic.0.030205-0.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
FEMS Microbiol Rev 2002; 26:49-71; PMID:12007642; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00598.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2003; 69:1-9; PMID:12513970; http://dx.doi.org/10.1128/AEM.69.1.1-9.2003.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Gut Pathog 2010; 2:20; PMID:21143981; http://dx.doi.org/10.1186/1757-4749-2-20.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2001; 67:2571-7; PMID:11375165; http://dx.doi.org/10.1128/AEM.67.6.2571-2577.2001.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2001; 67:2692-8; PMID:11375182; http://dx.doi.org/10.1128/AEM.67.6.2692-2698.2001.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2000; 66:4696-704; PMID:11055912; http://dx.doi.org/10.1128/AEM.66.11.4696-4704.2000.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Bacteriol 2003; 185:7140-4; PMID:14645273; http://dx.doi.org/10.1128/JB.185.24.7140-7144.2003.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Int J Food Microbiol 2000; 60:261-8; PMID:11016615; http://dx.doi.org/10.1016/S0168-1605(00)00316-0.14.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2002; 68:4710-6; PMID:12324311; http://dx.doi.org/10.1128/AEM.68.10.4710-4716.2002.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2004; 70:2912-8; PMID:15128551; http://dx.doi.org/10.1128/AEM.70.5.2912-2918.2004.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Bacteriol 2002; 184:4177-86; PMID:12107135; http://dx.doi.org/10.1128/JB.184.15.4177-4186.2002.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2003; 69:7492-8; PMID:14660402; http://dx.doi.org/10.1128/AEM.69.12.7492-7498.2003.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Mol Microbiol 1998; 29:285-96; PMID:9701821; http://dx.doi.org/10.1046/j.1365-2958.1998.00929.x.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Bacteriol 2013; 195:510-22; PMID:23175650; http://dx.doi.org/10.1128/JB.01505-12.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Mol Microbiol 1989; 3:1287-94; PMID:2552265; http://dx.doi.org/10.1111/j.1365-2958.1989.tb00279.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Biol Chem 1995; 270:16701-13; PMID:7622480; http://dx.doi.org/10.1074/jbc.270.28.16701.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Cell 1988; 52:569-84; PMID:2830029; http://dx.doi.org/10.1016/0092-8674(88)90470-9.26.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Cell 1992; 71:255-65; PMID:1423593; http://dx.doi.org/10.1016/0092-8674(92)90354-F .,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Mol Biol 1988; 202:471-82; PMID:3050126; http://dx.doi.org/10.1016/0022-2836(88)90279-3.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Mol Microbiol 1992; 6:1861-6; PMID:1508037; http://dx.doi.org/10.1111/j.1365-2958.1992.tb01358.x.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Curr Microbiol 1997; 35:309-15; PMID:9462962; http://dx.doi.org/10.1007/s002849900260.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Mol Microbiol 1994; 11:933-41; PMID:8022269; http://dx.doi.org/10.1111/j.1365-2958.1994.tb00372.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Int J Food Microbiol 2006; 112:288-90; PMID:16806551; http://dx.doi.org/10.1016/j.ijfood - micro.2006.04.026.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2006; 72:5104-7; PMID:16820516; http://dx.doi.org/10.1128/AEM.02626-05.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Med Hypotheses 2007; 69:1323-4; PMID:17452083; http://dx.doi.org/10.1016/j.mehy.2007.03.007.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Methods Mol Biol 2012; 852:61-76; PMID:22328426; http://dx.doi.org/10.1007/978-1-61779-564-0_6.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2006; 72:2170-7; PMID:16517668; http://dx.doi.org/10.1128/AEM.72.3.2170-2177.2006.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Microbiology 2007; 153:3563-71; PMID:17906153; http://dx.doi.org/10.1099/mic.0.2007/006510-0.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Science   2008; 321:1294-5; PMID:18772416; http://dx.doi.org/10.1126/science.321.5894.1294b.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Lett Appl Microbiol 2008; 46:143-7; PMID:18028323; http://dx.doi.org/10.1111/j.1472-765X.2007.02293.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J B iomed Biotechnol 2009;  2009:275287; PMID:19753318; http://dx.doi.org/10.1155/2009/275287.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Curr Opin Biotechnol 2006; 17:211-6; PMID:16459072; http://dx.doi.org/10.1016/j.copbio.2006.01.006.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Mol Gen Genet 1995; 246:783-6; PMID:7898450; http://dx.doi.org/10.1007/BF00290728.,Non-OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Gene 1982; 19:259-68; PMID:6295879; http://dx.doi.org/10.1016/0378-1119(82)90015-4.44.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Gene 1990; 94:129-32; PMID:2121618; http://dx.doi.org/10.1016/0378-1119(90)90479-B.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
Appl Environ Microbiol 2001; 67:4560-5; PMID:11571156; http://dx.doi.org/10.1128/AEM.67.10.4560-4565.2001.47.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
FEMS Microbiol Lett 1998; 158:45-50; PMID:9453154; http://dx.doi.org/10.1111/j.1574-6968.1998.tb12798.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
J Appl Microbiol 2011; 110:618-30; PMID:21223465; http://dx.doi.org/10.1111/j.1365-2672.2010.04924.x.,OADS,/arxiv_data1/oa_pdf/86/3a/bbug-4-401.PMC3937201.pdf
"casei  strain LAB6,  *Correspondence to: Per EJ Saris; Email: per.saris@helsinki.fi Submitted: 05/17/2013; Revised: 06/20/2013; Accepted: 06/25/2013http://dx.doi.org/10.4161/bioe.25543Proline iminopeptidase PepI   overexpressing Lactobacillus casei    as an adjunct starter in Edam cheese sahar Navidghasemizad, Timo M Takala, Tapani alato ssava, and Per eJ saris* Department of Food and envir onmental scien ces; University of helsi nki; helsi nki, Finland Keywords:  Edam cheese, bitterness, PepI, proline  In this study the growth of genetically modified Lactobacillus casei  LaB6, ov erexpressing proline iminopeptidase PepI  and its capacity to increase free proline was investigated during ripening of edam che ese.",Non-OADS,/arxiv_data1/oa_pdf/66/9c/bbug-4-408.PMC3937202.pdf
Appl Microbiol Biotechnol 2006; 71:394-406; PMID:16628446 ;  http://dx.doi.org/10.1007/s00253-006-0427-1 4.,Non-OADS,/arxiv_data1/oa_pdf/66/9c/bbug-4-408.PMC3937202.pdf
J Dairy Sci  1995; 78:251-9; http://dx.doi.org/10.3168/jds.S0022-0302(95)76632-2 5.,Non-OADS,/arxiv_data1/oa_pdf/66/9c/bbug-4-408.PMC3937202.pdf
J Dairy Sci 2000; 83:609-19; PMID:10791774 ; http://dx.doi.org/10.3168/jds.,OADS,/arxiv_data1/oa_pdf/66/9c/bbug-4-408.PMC3937202.pdf
